<?xml version="1.0" encoding="UTF-8"?>
<aggregateKnowledgeResponse xmlns="http://www.w3.org/2005/Atom">
	<feed>
		<title>Initial treatment of moderately to severely active rheumatoid arthritis in adults</title>
		<category term="C0001975" scheme="gov.nih.nlm.semanticType.phsu" label="alcohol"/>
		<category term="C0002771" scheme="gov.nih.nlm.semanticType.phsu" label="analgesic"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
		<category term="C0003191" scheme="gov.nih.nlm.semanticType.phsu" label="antirheumatic"/>
		<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
		<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAID"/>
		<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAIDs"/>
		<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="Nonsteroidal antiinflammatory drugs"/>
		<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="nonsteroidal antiinflammatory drugs"/>
		<category term="C0005527" scheme="gov.nih.nlm.semanticType.topp" label="biologic therapies"/>
		<category term="C0009574" scheme="gov.nih.nlm.semanticType.phsu" label="preparation"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drug"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0020336" scheme="gov.nih.nlm.semanticType.phsu" label="hydroxychloroquine"/>
		<category term="C0021081" scheme="gov.nih.nlm.semanticType.imft" label="immunosuppressive"/>
		<category term="C0021488" scheme="gov.nih.nlm.semanticType.topp" label="Intraarticular injections"/>
		<category term="C0021488" scheme="gov.nih.nlm.semanticType.topp" label="intraarticular injections"/>
		<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
		<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="methotrexate"/>
		<category term="C0025815" scheme="gov.nih.nlm.semanticType.horm" label="methylprednisolone"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
		<category term="C0035448" scheme="gov.nih.nlm.semanticType.imft" label="rheumatoid factor"/>
		<category term="C0036078" scheme="gov.nih.nlm.semanticType.phsu" label="Sulfasalazine"/>
		<category term="C0036078" scheme="gov.nih.nlm.semanticType.phsu" label="sulfasalazine"/>
		<category term="C0040864" scheme="gov.nih.nlm.semanticType.phsu" label="triamcinolone"/>
		<category term="C0042196" scheme="gov.nih.nlm.semanticType.topp" label="vaccinations"/>
		<category term="C0047166" scheme="gov.nih.nlm.semanticType.phsu" label="acetaminophen"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0051259" scheme="gov.nih.nlm.semanticType.aapp" label="alpha inhibitors"/>
		<category term="C0062527" scheme="gov.nih.nlm.semanticType.imft" label="hepatitis B"/>
		<category term="C0063041" scheme="gov.nih.nlm.semanticType.phsu" label="leflunomide"/>
		<category term="C0073983" scheme="gov.nih.nlm.semanticType.phsu" label="salsalate"/>
		<category term="C0077004" scheme="gov.nih.nlm.semanticType.phsu" label="triamcinolone hexacetonide"/>
		<category term="C0085174" scheme="gov.nih.nlm.semanticType.phsu" label="misoprostol"/>
		<category term="C0086129" scheme="gov.nih.nlm.semanticType.phsu" label="depot preparation"/>
		<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
		<category term="C0173022" scheme="gov.nih.nlm.semanticType.orch" label="barriers"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
		<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
		<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="disease modifying antirheumatic drugs"/>
		<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="disease-modifying antirheumatic drug"/>
		<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="disease-modifying antirheumatic drugs"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0368582" scheme="gov.nih.nlm.semanticType.imft" label="antibodies"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0418967" scheme="gov.nih.nlm.semanticType.topp" label="other therapies"/>
		<category term="C0441640" scheme="gov.nih.nlm.semanticType.hlca" label="tapered"/>
		<category term="C0451615" scheme="gov.nih.nlm.semanticType.topp" label="pain relief"/>
		<category term="C0454366" scheme="gov.nih.nlm.semanticType.topp" label="stepped up"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0538927" scheme="gov.nih.nlm.semanticType.phsu" label="celecoxib"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapies"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="meet"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0644813" scheme="gov.nih.nlm.semanticType.orch" label="spectrum"/>
		<category term="C0666743" scheme="gov.nih.nlm.semanticType.imft" label="infliximab"/>
		<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
		<category term="C0717758" scheme="gov.nih.nlm.semanticType.imft" label="Etanercept"/>
		<category term="C0717758" scheme="gov.nih.nlm.semanticType.imft" label="etanercept"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C1122087" scheme="gov.nih.nlm.semanticType.imft" label="adalimumab"/>
		<category term="C1175945" scheme="gov.nih.nlm.semanticType.phsu" label="COX"/>
		<category term="C1293132" scheme="gov.nih.nlm.semanticType.topp" label="anchor"/>
		<category term="C1317433" scheme="gov.nih.nlm.semanticType.imft" label="human antichimeric antibodies"/>
		<category term="C1440782" scheme="gov.nih.nlm.semanticType.imft" label="human antichimeric"/>
		<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
		<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="tumor necrosis factor"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="act"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alpha"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="Drug therapy"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapies"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptide"/>
		<category term="C2974226" scheme="gov.nih.nlm.semanticType.orch" label="salicylate"/>
		<category term="C3177188" scheme="gov.nih.nlm.semanticType.topp" label="therapy early"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="Glucocorticoids"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C3541968" scheme="gov.nih.nlm.semanticType.phsu" label="opioids"/>
		<category term="C3657204" scheme="gov.nih.nlm.semanticType.imft" label="monoclonal antibody"/>		<id>7491</id>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H2"/>
			<id>198682</id>
			<summary>
				<section label="DEFINITION OF MODERATELY TO SEVERELY ACTIVE RA" id="2">
					<fragment>Patients with moderately to severely active RA are at greater risk of developing joint damage and disability than patients with mildly active disease.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H2"/>
			<id>198686</id>
			<summary>
				<section label="DEFINITION OF MODERATELY TO SEVERELY ACTIVE RA" id="2">
					<fragment>Evidence of inflammation on plain radiography of the hands, wrists, or feet, such as osteopenia and/or periarticular swelling.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3692872"/>
			<id>198692</id>
			<summary>
				<section label="GENERAL PRINCIPLES" id="3692872">
					<fragment>Treatment of all patients diagnosed with RA with disease-modifying antirheumatic drug (DMARD) therapy.</fragment>
				</section>
			</summary>
			<category term="C0003191" scheme="gov.nih.nlm.semanticType.phsu" label="antirheumatic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="disease-modifying antirheumatic drug"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H5"/>
			<id>198697</id>
			<summary>
				<section label="APPROACH TO DRUG THERAPY" id="5">
					<fragment>Our approach to therapy is based upon the widely favored view that all patients diagnosed with RA should receive DMARDs to prevent, arrest, or retard disease-related injury, as described above.</fragment>
				</section>
			</summary>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H5"/>
			<id>198698</id>
			<summary>
				<section label="APPROACH TO DRUG THERAPY" id="5">
					<fragment>Recommendations of major groups support the early use of disease-modifying antirheumatic drugs (DMARDs), usually methotrexate (MTX), for most patients with active disease.</fragment>
				</section>
			</summary>
			<category term="C0003191" scheme="gov.nih.nlm.semanticType.phsu" label="antirheumatic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="methotrexate"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="disease-modifying antirheumatic drugs"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H5"/>
			<id>198699</id>
			<summary>
				<section label="APPROACH TO DRUG THERAPY" id="5">
					<fragment>In some patients with mild disease, particularly those with minimal or low levels of disease activity, we use hydroxychloroquine or sulfasalazine, as described elsewhere.</fragment>
				</section>
			</summary>
			<category term="C0020336" scheme="gov.nih.nlm.semanticType.phsu" label="hydroxychloroquine"/>
			<category term="C0036078" scheme="gov.nih.nlm.semanticType.phsu" label="sulfasalazine"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H5"/>
			<id>198700</id>
			<summary>
				<section label="APPROACH TO DRUG THERAPY" id="5">
					<fragment>The following is our general approach to the selection of drug therapies for the initial therapy of patients with moderately to severely active RA.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapies"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H5"/>
			<id>198702</id>
			<summary>
				<section label="APPROACH TO DRUG THERAPY" id="5">
					<fragment>We initiate therapy with a DMARD or combinations of DMARDs.</fragment>
				</section>
			</summary>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H5"/>
			<id>198704</id>
			<summary>
				<section label="APPROACH TO DRUG THERAPY" id="5">
					<fragment>In patients unable to take MTX, we use monotherapy with a TNF inhibitor (eg, etanercept or adalimumab), leflunomide, or sulfasalazine.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0036078" scheme="gov.nih.nlm.semanticType.phsu" label="sulfasalazine"/>
			<category term="C0063041" scheme="gov.nih.nlm.semanticType.phsu" label="leflunomide"/>
			<category term="C0717758" scheme="gov.nih.nlm.semanticType.imft" label="etanercept"/>
			<category term="C1122087" scheme="gov.nih.nlm.semanticType.imft" label="adalimumab"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H5"/>
			<id>198705</id>
			<summary>
				<section label="APPROACH TO DRUG THERAPY" id="5">
					<fragment>We add nonsteroidal antiinflammatory drugs (NSAIDs) and/or glucocorticoids (systemic and/or intraarticular) for initial symptomatic control of inflammation, while awaiting the response to DMARD therapy.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="nonsteroidal antiinflammatory drugs"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3981569"/>
			<id>198708</id>
			<summary>
				<section label="DMARD THERAPY" id="3981569">
					<fragment>We initially use one of the more effective disease modifying antirheumatic drugs (DMARDs), usually methotrexate, both to suppress synovitis and other signs and symptoms of active disease and to prevent articular bone erosions and joint space narrowing.</fragment>
				</section>
			</summary>
			<category term="C0003191" scheme="gov.nih.nlm.semanticType.phsu" label="antirheumatic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="methotrexate"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="disease modifying antirheumatic drugs"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3981569"/>
			<id>198709</id>
			<summary>
				<section label="DMARD THERAPY" id="3981569">
					<fragment>We initiate DMARD therapy early in the treatment of RA because delayed use of such medications results in poorer physical function and in increased joint injury.</fragment>
				</section>
			</summary>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C3177188" scheme="gov.nih.nlm.semanticType.topp" label="therapy early"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3981569"/>
			<id>198710</id>
			<summary>
				<section label="DMARD THERAPY" id="3981569">
					<fragment>Numerous meta-analyses and randomized, controlled trials support the use of nonbiologic (traditional) and biologic DMARDs in patients with active RA.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3981569"/>
			<id>198712</id>
			<summary>
				<section label="DMARD THERAPY" id="3981569">
					<fragment>The applicability of these studies to the initial treatment of patients with active disease is addressed together with the other evidence described below.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3981576"/>
			<id>198713</id>
			<summary>
				<section label="Pretreatment interventions" id="3981576">
					<fragment>We take a number of important precautions before using DMARDs, including laboratory assessment (complete blood count, serum creatinine, aminotransferases, and other studies as indicated), evaluation of comorbidities, vaccinations, and screening for hepatitis C, hepatitis B, and latent tuberculosis infection.</fragment>
				</section>
			</summary>
			<category term="C0042196" scheme="gov.nih.nlm.semanticType.topp" label="vaccinations"/>
			<category term="C0062527" scheme="gov.nih.nlm.semanticType.imft" label="hepatitis B"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3981576"/>
			<id>198714</id>
			<summary>
				<section label="Pretreatment interventions" id="3981576">
					<fragment>A chest radiograph should be obtained prior to initiating treatment with methotrexate.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="methotrexate"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3981583"/>
			<id>198716</id>
			<summary>
				<section label="Initial therapy with methotrexate" id="3981583">
					<fragment>We recommend methotrexate (MTX) as the DMARD of choice for the initial treatment of patients with moderately to severely active RA.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="methotrexate"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3981583"/>
			<id>198717</id>
			<summary>
				<section label="Initial therapy with methotrexate" id="3981583">
					<fragment>MTX typically serves as the "anchor" drug for the most commonly used DMARD combinations.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C1293132" scheme="gov.nih.nlm.semanticType.topp" label="anchor"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3981583"/>
			<id>198719</id>
			<summary>
				<section label="Initial therapy with methotrexate" id="3981583">
					<fragment>MTX is contraindicated in several groups of patients.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3981583"/>
			<id>198722</id>
			<summary>
				<section label="Initial therapy with methotrexate" id="3981583">
					<fragment>Patients with liver disease or excessive alcohol intake.</fragment>
				</section>
			</summary>
			<category term="C0001975" scheme="gov.nih.nlm.semanticType.phsu" label="alcohol"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3981583"/>
			<id>198723</id>
			<summary>
				<section label="Initial therapy with methotrexate" id="3981583">
					<fragment>Patients with severe renal impairment (estimated glomerular filtration rate less than 30 mL/min).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982770"/>
			<id>198727</id>
			<summary>
				<section label="MTX dosing" id="3982770">
					<fragment>We suggest initiating therapy at a dose between 7.5 and 15 mg once weekly for most patients, depending upon the degree of disease activity, the size and age of the patient, the presence of comorbidities, and renal function.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982770"/>
			<id>198728</id>
			<summary>
				<section label="MTX dosing" id="3982770">
					<fragment>As examples, we would treat a 70-year-old patient weighing 55 kg with moderately active disease with an initial dose of 7.5 mg once weekly, while an otherwise healthy 30-year-old patient weighing 80 kg with highly active disease would be started on 15 mg once weekly.</fragment>
				</section>
			</summary>
			<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982770"/>
			<id>198729</id>
			<summary>
				<section label="MTX dosing" id="3982770">
					<fragment>A lower initial dose is essential in patients with reduced renal function, defined as an estimated glomerular filtration rate (eGFR) &lt;60 mL/min.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982770"/>
			<id>198730</id>
			<summary>
				<section label="MTX dosing" id="3982770">
					<fragment>The MTX dose is increased as tolerated and as needed to control symptoms and signs of arthritis.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982770"/>
			<id>198732</id>
			<summary>
				<section label="MTX dosing" id="3982770">
					<fragment>In patients with continued high disease activity, we may increase by up to 5 mg/week, if few comorbidities are present and if the increase in the dose continues to be well-tolerated.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982770"/>
			<id>198736</id>
			<summary>
				<section label="MTX dosing" id="3982770">
					<fragment>In early RA trials in which the dose of MTX is rapidly increased to 20 mg/week and in which the drug is continued for at least three months, approximately 30 percent of patients achieve a DAS28 less than or equal to 3.2, consistent with low disease activity, within three to six months.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982770"/>
			<id>198737</id>
			<summary>
				<section label="MTX dosing" id="3982770">
					<fragment>For patients in whom 20 to 25 mg of MTX orally once weekly is ineffective or is poorly tolerated because of gastrointestinal symptoms, a trial of subcutaneous MTX administration is an alternative to switching to another DMARD or to adding a TNF inhibitor.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982770"/>
			<id>198739</id>
			<summary>
				<section label="MTX dosing" id="3982770">
					<fragment>It is imperative to tell the patient to take all the MTX over a single 24-hour period once a week, as spreading the dose out further may produce significant liver toxicity.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3984111"/>
			<id>198741</id>
			<summary>
				<section label="Side effects, monitoring, and other considerations" id="3984111">
					<fragment>The toxicities associated with MTX in the doses used in RA are very rarely life-threatening in patients receiving recommended monitoring.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3984111"/>
			<id>198745</id>
			<summary>
				<section label="Side effects, monitoring, and other considerations" id="3984111">
					<fragment>Patients receiving MTX should also receive daily supplementation with folic acid.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3984111"/>
			<id>198746</id>
			<summary>
				<section label="Side effects, monitoring, and other considerations" id="3984111">
					<fragment>The use of folic acid and additional considerations with the use of MTX that are discussed in more detail separately include alcohol ingestion and dosing in renal insufficiency.</fragment>
				</section>
			</summary>
			<category term="C0001975" scheme="gov.nih.nlm.semanticType.phsu" label="alcohol"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H207103444"/>
			<id>198748</id>
			<summary>
				<section label="MTX versus other DMARDs" id="207103444">
					<fragment>MTX has also been shown to improve survival (both cardiovascular and all-cause mortality) in patients with RA compared with other nonbiologic DMARDs.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H207103444"/>
			<id>198749</id>
			<summary>
				<section label="MTX versus other DMARDs" id="207103444">
					<fragment>However, practically all trials that originally led to the widespread use of MTX in this role were performed in patients with well-established RA, often after several years of disease, rather than soon after the initial development of inflammatory arthritis.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H207103444"/>
			<id>198752</id>
			<summary>
				<section label="MTX versus other DMARDs" id="207103444">
					<fragment>In randomized trials, initial therapy with MTX results in comparable benefit to initial therapy with a TNF inhibitor alone.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H207103451"/>
			<id>198754</id>
			<summary>
				<section label="MTX versus initial combination therapy" id="207103451">
					<fragment>Combinations of MTX with either sulfasalazine (SSZ) or hydroxychloroquine (HCQ), with both SSZ and HCQ, or with a biologic DMARD also have proven efficacy for initial treatment of highly active RA in patients with poor prognostic features.</fragment>
				</section>
			</summary>
			<category term="C0020336" scheme="gov.nih.nlm.semanticType.phsu" label="hydroxychloroquine"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0036078" scheme="gov.nih.nlm.semanticType.phsu" label="sulfasalazine"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H207103451"/>
			<id>198755</id>
			<summary>
				<section label="MTX versus initial combination therapy" id="207103451">
					<fragment>However, we prefer MTX monotherapy for initial treatment rather than in combination with other nonbiologic or biologic DMARDs or a biologic DMARD alone, despite the fact that a greater proportion of patients respond well when treated initially with combination therapies or biologics.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapies"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H207103451"/>
			<id>198758</id>
			<summary>
				<section label="MTX versus initial combination therapy" id="207103451">
					<fragment>Clinical outcomes after several years of treatment are similar in trials that compared patients initially receiving MTX, who then stepped up to combination therapy after an inadequate response, with patients initially treated with combination therapy.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0454366" scheme="gov.nih.nlm.semanticType.topp" label="stepped up"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H207103451"/>
			<id>198759</id>
			<summary>
				<section label="MTX versus initial combination therapy" id="207103451">
					<fragment>Long-term clinical outcomes between such groups are not well-studied.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H207103451"/>
			<id>198761</id>
			<summary>
				<section label="MTX versus initial combination therapy" id="207103451">
					<fragment>Compared with MTX, there is less information available regarding the long-term safety of biologic DMARDs, and there is some evidence that the risk may be greater with these agents.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H207103451"/>
			<id>198762</id>
			<summary>
				<section label="MTX versus initial combination therapy" id="207103451">
					<fragment>There are also widespread regulatory or cost barriers to the use of biologic therapies for initial DMARD treatment for most DMARD-naive patients, even with severely active RA.</fragment>
				</section>
			</summary>
			<category term="C0005527" scheme="gov.nih.nlm.semanticType.topp" label="biologic therapies"/>
			<category term="C0173022" scheme="gov.nih.nlm.semanticType.orch" label="barriers"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982784"/>
			<id>198763</id>
			<summary>
				<section label="Alternatives to MTX" id="3982784">
					<fragment>There are insufficient data to identify the optimal initial therapy in patients with moderately to severely active RA who are unable to take MTX.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982784"/>
			<id>198765</id>
			<summary>
				<section label="Alternatives to MTX" id="3982784">
					<fragment>The principal options are a tumor necrosis factor (TNF) inhibitor, leflunomide (LEF), or sulfasalazine (SSZ): For patients who are not restricted by regulatory or cost constraints, we suggest the use of a TNF inhibitor.</fragment>
				</section>
			</summary>
			<category term="C0036078" scheme="gov.nih.nlm.semanticType.phsu" label="sulfasalazine"/>
			<category term="C0063041" scheme="gov.nih.nlm.semanticType.phsu" label="leflunomide"/>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="tumor necrosis factor"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982784"/>
			<id>198766</id>
			<summary>
				<section label="Alternatives to MTX" id="3982784">
					<fragment>Among the available agents, etanercept is our first choice, followed by adalimumab.</fragment>
				</section>
			</summary>
			<category term="C0717758" scheme="gov.nih.nlm.semanticType.imft" label="etanercept"/>
			<category term="C1122087" scheme="gov.nih.nlm.semanticType.imft" label="adalimumab"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982784"/>
			<id>198768</id>
			<summary>
				<section label="Alternatives to MTX" id="3982784">
					<fragment>Data from randomized trials demonstrating the benefit of each agent compared with placebo, as well as head-to-head comparisons of MTX with TNF inhibitors and of MTX, LEF, and SSZ with each other, are reviewed in detail elsewhere.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982842"/>
			<id>198769</id>
			<summary>
				<section label="TNF inhibitors" id="3982842">
					<fragment>A number of biologic DMARDs, particularly the tumor necrosis factor (TNF)-alpha inhibitors, have been proven effective as monotherapy, compared with placebo or MTX, in randomized trials in patients with moderately and severely active RA.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0051259" scheme="gov.nih.nlm.semanticType.aapp" label="alpha inhibitors"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="tumor necrosis factor"/>
			<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alpha"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982842"/>
			<id>198771</id>
			<summary>
				<section label="TNF inhibitors" id="3982842">
					<fragment>In the patient who is unable to take methotrexate (MTX), we use either of the following TNF inhibitors for initial therapy: Etanercept - Etanercept has shown generally similar or modestly greater efficacy compared with MTX in randomized trials.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="methotrexate"/>
			<category term="C0717758" scheme="gov.nih.nlm.semanticType.imft" label="Etanercept"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982842"/>
			<id>198772</id>
			<summary>
				<section label="TNF inhibitors" id="3982842">
					<fragment>There is slightly longer experience with this agent, and there is indirect evidence of lower rates of serious infections compared with other biologic DMARDs, including adalimumab and infliximab.</fragment>
				</section>
			</summary>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C0666743" scheme="gov.nih.nlm.semanticType.imft" label="infliximab"/>
			<category term="C1122087" scheme="gov.nih.nlm.semanticType.imft" label="adalimumab"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982842"/>
			<id>198777</id>
			<summary>
				<section label="TNF inhibitors" id="3982842">
					<fragment>The use of adalimumab is supported by randomized trials showing comparable efficacy to MTX as initial DMARD monotherapy and by indirect comparisons in a meta-analysis of randomized trials showing comparable efficacy to other TNF inhibitors.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C1122087" scheme="gov.nih.nlm.semanticType.imft" label="adalimumab"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982842"/>
			<id>198780</id>
			<summary>
				<section label="TNF inhibitors" id="3982842">
					<fragment>Use of infliximab alone is generally NOT recommended due to the increased likelihood of developing inactivating human antichimeric antibodies (HACA) when this chimeric monoclonal antibody is given without other immunosuppressive drugs.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0021081" scheme="gov.nih.nlm.semanticType.imft" label="immunosuppressive"/>
			<category term="C0368582" scheme="gov.nih.nlm.semanticType.imft" label="antibodies"/>
			<category term="C0666743" scheme="gov.nih.nlm.semanticType.imft" label="infliximab"/>
			<category term="C1317433" scheme="gov.nih.nlm.semanticType.imft" label="human antichimeric antibodies"/>
			<category term="C1440782" scheme="gov.nih.nlm.semanticType.imft" label="human antichimeric"/>
			<category term="C3657204" scheme="gov.nih.nlm.semanticType.imft" label="monoclonal antibody"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982842"/>
			<id>198781</id>
			<summary>
				<section label="TNF inhibitors" id="3982842">
					<fragment>However, we recognize that, in clinical practice, some patients receive infliximab alone.</fragment>
				</section>
			</summary>
			<category term="C0666743" scheme="gov.nih.nlm.semanticType.imft" label="infliximab"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982842"/>
			<id>198782</id>
			<summary>
				<section label="TNF inhibitors" id="3982842">
					<fragment>Loss of efficacy due to emergence of HACA may be overcome by use of increasing doses or by increased frequency of administration of infliximab, although the increased cost associated with this approach may be prohibitive.</fragment>
				</section>
			</summary>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C0666743" scheme="gov.nih.nlm.semanticType.imft" label="infliximab"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982900"/>
			<id>198787</id>
			<summary>
				<section label="Nonbiologic DMARD alternatives to MTX" id="3982900">
					<fragment>In patients unable to take methotrexate (MTX), effective nonbiologic alternatives for initial therapy include leflunomide (LEF) and, in some patients, sulfasalazine (SSZ): Leflunomide - We use leflunomide (LEF) in patients who, for regulatory, insurance, or cost reasons, are unable to use MTX or a biologic DMARD for initial treatment.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="methotrexate"/>
			<category term="C0036078" scheme="gov.nih.nlm.semanticType.phsu" label="sulfasalazine"/>
			<category term="C0063041" scheme="gov.nih.nlm.semanticType.phsu" label="leflunomide"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982900"/>
			<id>198788</id>
			<summary>
				<section label="Nonbiologic DMARD alternatives to MTX" id="3982900">
					<fragment>We may also use LEF in patients who have a strong preference for an oral rather than a parenteral agent.</fragment>
				</section>
			</summary>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982900"/>
			<id>198790</id>
			<summary>
				<section label="Nonbiologic DMARD alternatives to MTX" id="3982900">
					<fragment>LEF has not been directly compared with the TNF inhibitors, but the superiority of TNF inhibitors is suggested by the comparability of LEF to sometimes suboptimal doses of MTX and to SSZ;</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982900"/>
			<id>198791</id>
			<summary>
				<section label="Nonbiologic DMARD alternatives to MTX" id="3982900">
					<fragment>by the more rapid effects and greater overall benefit of TNF inhibitors when they have been directly compared with MTX or SSZ;</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982900"/>
			<id>198794</id>
			<summary>
				<section label="Nonbiologic DMARD alternatives to MTX" id="3982900">
					<fragment>Among nonbiologic DMARDs, we prefer LEF over SSZ because of its possible greater effectiveness for the treatment of severely active RA, regardless of the presence or absence of poor prognostic factors.</fragment>
				</section>
			</summary>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982900"/>
			<id>198795</id>
			<summary>
				<section label="Nonbiologic DMARD alternatives to MTX" id="3982900">
					<fragment>Some randomized trials suggest that LEF is more effective than SSZ in achieving a clinical response, in decreasing functional disability, and in reducing progression of erosive changes;</fragment>
				</section>
			</summary>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982900"/>
			<id>198797</id>
			<summary>
				<section label="Nonbiologic DMARD alternatives to MTX" id="3982900">
					<fragment>Additionally, the adverse effect profile of LEF is generally similar to that of MTX, with similar rates of withdrawal for drug toxicity at two years.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982900"/>
			<id>198798</id>
			<summary>
				<section label="Nonbiologic DMARD alternatives to MTX" id="3982900">
					<fragment>The drug should be used with caution in patients with renal insufficiency.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982900"/>
			<id>198800</id>
			<summary>
				<section label="Nonbiologic DMARD alternatives to MTX" id="3982900">
					<fragment>Sulfasalazine - We limit the use of sulfasalazine (SSZ) as an alternative to MTX to patients who do not have any poor prognostic features, who have a strong preference for an oral agent, and in whom LEF is contraindicated.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0036078" scheme="gov.nih.nlm.semanticType.phsu" label="Sulfasalazine"/>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3982900"/>
			<id>198801</id>
			<summary>
				<section label="Nonbiologic DMARD alternatives to MTX" id="3982900">
					<fragment>SSZ alone (begun at 500 mg twice daily and gradually increased [eg, by 500 mg per week] to up to 1000 mg two or three times daily) or in combination with hydroxychloroquine can be effective as the only DMARD in patients with early, severely active RA who lack poor prognostic factors.</fragment>
				</section>
			</summary>
			<category term="C0020336" scheme="gov.nih.nlm.semanticType.phsu" label="hydroxychloroquine"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3694939"/>
			<id>198809</id>
			<summary>
				<section label="SYMPTOMATIC TREATMENT WITH ANTIINFLAMMATORY DRUGS" id="3694939">
					<fragment>Nonsteroidal antiinflammatory drugs (NSAIDs) and/or glucocorticoids act rapidly to control inflammation but do not provide adequate benefit for longer-term control of disease or for prevention of joint injury in most patients.</fragment>
				</section>
			</summary>
			<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="Nonsteroidal antiinflammatory drugs"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="act"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3694939"/>
			<id>198810</id>
			<summary>
				<section label="SYMPTOMATIC TREATMENT WITH ANTIINFLAMMATORY DRUGS" id="3694939">
					<fragment>Moreover, chronic use of these agents, particularly glucocorticoids in moderate to high doses, is associated with significant risk of adverse effects.</fragment>
				</section>
			</summary>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3694939"/>
			<id>198811</id>
			<summary>
				<section label="SYMPTOMATIC TREATMENT WITH ANTIINFLAMMATORY DRUGS" id="3694939">
					<fragment>We, thus, use these medications primarily for temporary control of disease activity in patients in whom treatment is being started with disease-modifying antirheumatic drugs (DMARDs) or in whom adjunctive treatment is needed for persistent or flaring disease until treatment with DMARDs is sufficiently effective.</fragment>
				</section>
			</summary>
			<category term="C0003191" scheme="gov.nih.nlm.semanticType.phsu" label="antirheumatic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="disease-modifying antirheumatic drugs"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3694939"/>
			<id>198812</id>
			<summary>
				<section label="SYMPTOMATIC TREATMENT WITH ANTIINFLAMMATORY DRUGS" id="3694939">
					<fragment>Some patients require ongoing use of such agents despite other therapies, but neither NSAIDs nor glucocorticoids should be considered as substitutes for effective treatment with DMARDs.</fragment>
				</section>
			</summary>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAIDs"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C0418967" scheme="gov.nih.nlm.semanticType.topp" label="other therapies"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3694939"/>
			<id>198813</id>
			<summary>
				<section label="SYMPTOMATIC TREATMENT WITH ANTIINFLAMMATORY DRUGS" id="3694939">
					<fragment>We use NSAIDs initially in most patients with moderately to severely active disease.</fragment>
				</section>
			</summary>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAIDs"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3694939"/>
			<id>198814</id>
			<summary>
				<section label="SYMPTOMATIC TREATMENT WITH ANTIINFLAMMATORY DRUGS" id="3694939">
					<fragment>We also initiate therapy with glucocorticoids in patients on the more severe end of this spectrum, while patients with less active disease who do not respond adequately to NSAIDs within two weeks should also receive treatment with glucocorticoids.</fragment>
				</section>
			</summary>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAIDs"/>
			<category term="C0644813" scheme="gov.nih.nlm.semanticType.orch" label="spectrum"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3693478"/>
			<id>198815</id>
			<summary>
				<section label="NSAIDs" id="3693478">
					<fragment>NSAIDs should be used at full therapeutic antiinflammatory doses for initial therapy of patients with moderately to severely active RA, unless contraindicated by gastrointestinal or renal disease or by heart failure.</fragment>
				</section>
			</summary>
			<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAIDs"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3693478"/>
			<id>198822</id>
			<summary>
				<section label="NSAIDs" id="3693478">
					<fragment>In patients at increased risk of NSAID gastropathy, such as those who are also receiving glucocorticoids or who have a history of peptic ulcer disease, appropriate measures should be undertaken to decrease risk of gastrointestinal complications such as use of a proton pump inhibitor, misoprostol, or possibly use of a selective COX-2 inhibitor (eg, celecoxib) rather than a nonselective NSAID.</fragment>
				</section>
			</summary>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAID"/>
			<category term="C0085174" scheme="gov.nih.nlm.semanticType.phsu" label="misoprostol"/>
			<category term="C0538927" scheme="gov.nih.nlm.semanticType.phsu" label="celecoxib"/>
			<category term="C1175945" scheme="gov.nih.nlm.semanticType.phsu" label="COX"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3693478"/>
			<id>198823</id>
			<summary>
				<section label="NSAIDs" id="3693478">
					<fragment>Alternatives to the non-salicylate NSAIDs in such patients also include the non-acetylated salicylates (eg, salsalate at 2000 to 3000 mg/day), which have proven antiinflammatory activity with fewer adverse gastrointestinal effects.</fragment>
				</section>
			</summary>
			<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAIDs"/>
			<category term="C0073983" scheme="gov.nih.nlm.semanticType.phsu" label="salsalate"/>
			<category term="C2974226" scheme="gov.nih.nlm.semanticType.orch" label="salicylate"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3693478"/>
			<id>198825</id>
			<summary>
				<section label="NSAIDs" id="3693478">
					<fragment>Effective management with DMARDs should allow for the discontinuation of daily full-dose NSAID use.</fragment>
				</section>
			</summary>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAID"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3693478"/>
			<id>198826</id>
			<summary>
				<section label="NSAIDs" id="3693478">
					<fragment>Therapeutic trials of individual NSAIDs can continue until the patient has achieved adequate control of the inflammation with minimal side effects.</fragment>
				</section>
			</summary>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAIDs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3693989"/>
			<id>198829</id>
			<summary>
				<section label="Glucocorticoids" id="3693989">
					<fragment>Glucocorticoids act to rapidly reduce symptoms due to inflammatory synovitis in patients with RA.</fragment>
				</section>
			</summary>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="act"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="Glucocorticoids"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3693989"/>
			<id>198833</id>
			<summary>
				<section label="Glucocorticoids" id="3693989">
					<fragment>There is also evidence that glucocorticoids retard radiographic progression in patients with RA in the short to medium term.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3695299"/>
			<id>198835</id>
			<summary>
				<section label="Oral glucocorticoids" id="3695299">
					<fragment>We suggest the use of oral glucocorticoids to help control disease activity in the initial treatment of severely active RA, particularly in early disease, and in the treatment of patients with less severe disease in whom a trial of NSAIDs has been inadequate.</fragment>
				</section>
			</summary>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAIDs"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3695299"/>
			<id>198836</id>
			<summary>
				<section label="Oral glucocorticoids" id="3695299">
					<fragment>We use glucocorticoids in addition to NSAIDs because of their extremely rapid onset of action and the greater effectiveness in controlling symptoms for most patients with active RA.</fragment>
				</section>
			</summary>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAIDs"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3695299"/>
			<id>198839</id>
			<summary>
				<section label="Oral glucocorticoids" id="3695299">
					<fragment>Glucocorticoids should then be tapered as rapidly as tolerated with the goal of further tapering and eventual discontinuation, if possible, once disease control is achieved and can be maintained.</fragment>
				</section>
			</summary>
			<category term="C0441640" scheme="gov.nih.nlm.semanticType.hlca" label="tapered"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="Glucocorticoids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3695299"/>
			<id>198844</id>
			<summary>
				<section label="Oral glucocorticoids" id="3695299">
					<fragment>There are numerous risks associated with glucocorticoid use, and appropriate monitoring and precautions should be performed in all patients on these medications with respect to risks for osteoporosis, diabetes, and other adverse effects of hypercortisolism.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H1487863"/>
			<id>198846</id>
			<summary>
				<section label="Intramuscular glucocorticoids" id="1487863">
					<fragment>In patients who must avoid daily oral glucocorticoids or who require an extremely rapid antiinflammatory response, an alternative to oral glucocorticoids is a single initial intramuscular injection of a depot preparation of methylprednisolone (80 to 120 mg), administered by deep intramuscular injection into the gluteal muscle.</fragment>
				</section>
			</summary>
			<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
			<category term="C0009574" scheme="gov.nih.nlm.semanticType.phsu" label="preparation"/>
			<category term="C0025815" scheme="gov.nih.nlm.semanticType.horm" label="methylprednisolone"/>
			<category term="C0086129" scheme="gov.nih.nlm.semanticType.phsu" label="depot preparation"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3985847"/>
			<id>198849</id>
			<summary>
				<section label="Intraarticular glucocorticoids" id="3985847">
					<fragment>Intraarticular injections of long-acting glucocorticoids (eg, triamcinolone hexacetonide) are used to reduce synovitis in particular joints that are more inflamed than others.</fragment>
				</section>
			</summary>
			<category term="C0021488" scheme="gov.nih.nlm.semanticType.topp" label="Intraarticular injections"/>
			<category term="C0040864" scheme="gov.nih.nlm.semanticType.phsu" label="triamcinolone"/>
			<category term="C0077004" scheme="gov.nih.nlm.semanticType.phsu" label="triamcinolone hexacetonide"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3985847"/>
			<id>198850</id>
			<summary>
				<section label="Intraarticular glucocorticoids" id="3985847">
					<fragment>In such patients, it may be difficult to distinguish between active joint inflammation due to RA alone and that due to infection.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H2986439"/>
			<id>198852</id>
			<summary>
				<section label="ANALGESICS" id="2986439">
					<fragment>In addition to the medications noted above, we use analgesic medications, such as acetaminophen, for additional pain relief if required.</fragment>
				</section>
			</summary>
			<category term="C0002771" scheme="gov.nih.nlm.semanticType.phsu" label="analgesic"/>
			<category term="C0047166" scheme="gov.nih.nlm.semanticType.phsu" label="acetaminophen"/>
			<category term="C0451615" scheme="gov.nih.nlm.semanticType.topp" label="pain relief"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H2986439"/>
			<id>198853</id>
			<summary>
				<section label="ANALGESICS" id="2986439">
					<fragment>We avoid the use of opioids because pain can be controlled in most patients with RA by effective use of NSAIDs, glucocorticoids, and DMARDs that control the disease process.</fragment>
				</section>
			</summary>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAIDs"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="C3541968" scheme="gov.nih.nlm.semanticType.phsu" label="opioids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H2986439"/>
			<id>198854</id>
			<summary>
				<section label="ANALGESICS" id="2986439">
					<fragment>Patients without evidence of very significant joint injury who appear to require opioids for adequate pain relief despite good control of disease activity should be evaluated for other comorbid conditions.</fragment>
				</section>
			</summary>
			<category term="C0451615" scheme="gov.nih.nlm.semanticType.topp" label="pain relief"/>
			<category term="C3541968" scheme="gov.nih.nlm.semanticType.phsu" label="opioids"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H21"/>
			<id>198855</id>
			<summary>
				<section label="MONITORING AND REEVALUATION" id="21">
					<fragment>Disease activity and the response to therapy should be regularly reassessed, along with monitoring for drug toxicities, every three to five weeks until the patient is stable and disease is under control.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H21"/>
			<id>198859</id>
			<summary>
				<section label="MONITORING AND REEVALUATION" id="21">
					<fragment>We periodically reevaluate disease activity using a quantitative composite measure at each assessment.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H21"/>
			<id>198861</id>
			<summary>
				<section label="MONITORING AND REEVALUATION" id="21">
					<fragment>more frequent clinical assessments may be required in patients experiencing a flare of disease or undergoing changes in therapy.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3985983"/>
			<id>198863</id>
			<summary>
				<section label="Disease resistant to initial symptomatic treatment" id="3985983">
					<fragment>We take the following approaches in patients who exhibit a persistent inflammatory synovitis that is resistant to the initial symptomatic therapies described above: We add oral glucocorticoids in patients begun on NSAIDs and DMARDs who continue to experience significant symptoms after 10 to 14 days of therapy.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAIDs"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3985983"/>
			<id>198864</id>
			<summary>
				<section label="Disease resistant to initial symptomatic treatment" id="3985983">
					<fragment>We use intraarticular glucocorticoids in individual joints when only a small number are resistant to therapy with systemic agents or if it is anticipated that a local injection may preclude the need for NSAIDs or systemic glucocorticoids.</fragment>
				</section>
			</summary>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAIDs"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3986034"/>
			<id>198865</id>
			<summary>
				<section label="Disease resistant to initial DMARD therapy" id="3986034">
					<fragment>We suggest that patients who fail to achieve remission or low disease activity within three to six months of initiating therapy or who require more than approximately 5 to 7.5 mg/day of prednisone or equivalent glucocorticoid chronically to maintain a state of remission or low disease activity receive a more potent DMARD or combination of DMARDs.</fragment>
				</section>
			</summary>
			<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3986086"/>
			<id>198867</id>
			<summary>
				<section label="Flares" id="3986086">
					<fragment>It is important to distinguish a disease flare, characterized by symptoms and physical and laboratory findings of increased inflammatory synovitis, from noninflammatory causes of local or generalized increased pain.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3986086"/>
			<id>198869</id>
			<summary>
				<section label="Flares" id="3986086">
					<fragment>Drug therapy for flares is discussed in detail elsewhere.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drug"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="Drug therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3697757"/>
			<id>198872</id>
			<summary>
				<section label="DURATION OF THERAPY" id="3697757">
					<fragment>Although some patients may tolerate a reduced dose of medications, whether or not to discontinue DMARDs in patients in remission remains controversial.</fragment>
				</section>
			</summary>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3697757"/>
			<id>198873</id>
			<summary>
				<section label="DURATION OF THERAPY" id="3697757">
					<fragment>We prefer to continue nonbiologic or biologic DMARD therapy at reduced doses, if possible, but do not discontinue DMARD therapy in most patients who have had moderately to severely active RA.</fragment>
				</section>
			</summary>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3697757"/>
			<id>198875</id>
			<summary>
				<section label="DURATION OF THERAPY" id="3697757">
					<fragment>As an example, in a patient in clinical remission being treated with prednisone (7.5 mg/day) and MTX (20 mg/week), we would first try to reduce prednisone because of the risk of long-term adverse effects with glucocorticoids.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3697757"/>
			<id>198877</id>
			<summary>
				<section label="DURATION OF THERAPY" id="3697757">
					<fragment>If prednisone can be discontinued, or cannot but can be lowered to a dose no greater than 5 mg/day, we next decrease MTX.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3697757"/>
			<id>198879</id>
			<summary>
				<section label="DURATION OF THERAPY" id="3697757">
					<fragment>A lower dose of MTX (eg, 10 to 12.5 mg/week) may be adequate to maintain remission in patients who are older or who have diminished renal function.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H3697757"/>
			<id>198881</id>
			<summary>
				<section label="DURATION OF THERAPY" id="3697757">
					<fragment>The risk of disease recurrence in such patients is high, and flares of disease may occur even several years after stopping therapy.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H23"/>
			<id>198894</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="23">
					<fragment>Patients with moderately to severely active rheumatoid arthritis (RA) typically meet the ACR/EULAR criteria for RA, have at least five inflamed joints and elevated acute phase reactants, usually have positive tests for rheumatoid factor and/or anticyclic citrullinated peptide antibodies, and sometimes exhibit early radiographic changes consistent with inflammatory arthritis and joint injury.</fragment>
				</section>
			</summary>
			<category term="C0035448" scheme="gov.nih.nlm.semanticType.imft" label="rheumatoid factor"/>
			<category term="C0368582" scheme="gov.nih.nlm.semanticType.imft" label="antibodies"/>
			<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="meet"/>
			<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptide"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H23"/>
			<id>198895</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="23">
					<fragment>In all patients with moderately to severely active RA, we recommend treatment with a disease modifying antirheumatic drugs (DMARD), rather than use of antiinflammatory agents and/or glucocorticoids alone and delay of DMARD therapy.</fragment>
				</section>
			</summary>
			<category term="C0003191" scheme="gov.nih.nlm.semanticType.phsu" label="antirheumatic"/>
			<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="disease modifying antirheumatic drugs"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H23"/>
			<id>198896</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="23">
					<fragment>Additional principles for the treatment of RA include achievement and maintenance of tight control of disease activity, with the ideal goal of remission;</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H23"/>
			<id>198899</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="23">
					<fragment>Patient education and other nonpharmacologic and preventive therapies are needed for all patients with RA.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H23"/>
			<id>198900</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="23">
					<fragment>We suggest that methotrexate (MTX) be used as the initial DMARD for patients with moderately to severely active RA, rather than another single nonbiologic or biologic DMARD or combination therapy.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="methotrexate"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H23"/>
			<id>198902</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="23">
					<fragment>Subcutaneous administration may be of benefit in patients with an inadequate response to orally administered MTX at a dose of 25 mg/week of MTX.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H23"/>
			<id>198903</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="23">
					<fragment>Alternative DMARDs for patients unable to take MTX include a tumor necrosis factor inhibitor, preferably etanercept or adalimumab, or leflunomide.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0063041" scheme="gov.nih.nlm.semanticType.phsu" label="leflunomide"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C0717758" scheme="gov.nih.nlm.semanticType.imft" label="etanercept"/>
			<category term="C1122087" scheme="gov.nih.nlm.semanticType.imft" label="adalimumab"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="tumor necrosis factor"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H23"/>
			<id>198904</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="23">
					<fragment>We limit the use of sulfasalazine as an alternative to MTX to patients who do not have any poor prognostic features, who have a strong preference for an oral agent, and in whom leflunomide is contraindicated.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0036078" scheme="gov.nih.nlm.semanticType.phsu" label="sulfasalazine"/>
			<category term="C0063041" scheme="gov.nih.nlm.semanticType.phsu" label="leflunomide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H23"/>
			<id>198905</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="23">
					<fragment>In patients with moderately to severely active RA, we use antiinflammatory drug therapy with nonsteroidal antiinflammatory drugs (NSAIDs) or glucocorticoids, preferably on a temporary basis, to quickly achieve control of signs and symptoms of disease.</fragment>
				</section>
			</summary>
			<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="nonsteroidal antiinflammatory drugs"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H23"/>
			<id>198906</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="23">
					<fragment>We use nonsteroidal antiinflammatory drugs (NSAIDs) in all patients without contraindications to their use.</fragment>
				</section>
			</summary>
			<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="nonsteroidal antiinflammatory drugs"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H23"/>
			<id>198907</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="23">
					<fragment>In patients with more severe disease or with moderate disease resistant to a brief course of NSAIDs, we suggest the use of glucocorticoids.</fragment>
				</section>
			</summary>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAIDs"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H23"/>
			<id>198909</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="23">
					<fragment>We use intraarticular injections of long-acting glucocorticoids to reduce synovitis in particular joints that are more inflamed than others.</fragment>
				</section>
			</summary>
			<category term="C0021488" scheme="gov.nih.nlm.semanticType.topp" label="intraarticular injections"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H23"/>
			<id>198911</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="23">
					<fragment>During the initial treatment of patients with moderately to severely active RA, the patient should be reevaluated every three to five weeks for the effectiveness of therapy and for the monitoring of possible drug toxicity.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H23"/>
			<id>198912</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="23">
					<fragment>We advise the periodic reevaluation of disease activity using a quantitative composite measure at each assessment.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7491#H23"/>
			<id>198913</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="23">
					<fragment>In patients who fail to achieve remission within three to six months of initiating therapy or who require more than approximately 5 to 7.5 mg/day of prednisone or equivalent glucocorticoid on a chronic basis to maintain a state of remission or low disease activity, we suggest using a more potent DMARD or combination of DMARDs rather than continuing the same treatment regimen for a longer period of time.</fragment>
				</section>
			</summary>
			<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults</title>
		<category term="C0002771" scheme="gov.nih.nlm.semanticType.phsu" label="analgesic"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
		<category term="C0003191" scheme="gov.nih.nlm.semanticType.phsu" label="antirheumatic"/>
		<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatories"/>
		<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
		<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAIDs"/>
		<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="nonsteroidal antiinflammatory drugs"/>
		<category term="C0004482" scheme="gov.nih.nlm.semanticType.phsu" label="Azathioprine"/>
		<category term="C0004482" scheme="gov.nih.nlm.semanticType.phsu" label="azathioprine"/>
		<category term="C0005527" scheme="gov.nih.nlm.semanticType.topp" label="biologic therapies"/>
		<category term="C0013162" scheme="gov.nih.nlm.semanticType.phsu" label="drug combinations"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="Pharmacotherapy"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drug"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="gold"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0020336" scheme="gov.nih.nlm.semanticType.phsu" label="hydroxychloroquine"/>
		<category term="C0020971" scheme="gov.nih.nlm.semanticType.topp" label="immunizations"/>
		<category term="C0021079" scheme="gov.nih.nlm.semanticType.topp" label="immunosuppressive therapy"/>
		<category term="C0021081" scheme="gov.nih.nlm.semanticType.imft" label="immunosuppressants"/>
		<category term="C0021081" scheme="gov.nih.nlm.semanticType.imft" label="immunosuppressive"/>
		<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
		<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="Methotrexate"/>
		<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="methotrexate"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
		<category term="C0033972" scheme="gov.nih.nlm.semanticType.topp" label="combined therapy"/>
		<category term="C0035448" scheme="gov.nih.nlm.semanticType.imft" label="rheumatoid factor"/>
		<category term="C0036078" scheme="gov.nih.nlm.semanticType.phsu" label="sulfasalazine"/>
		<category term="C0040610" scheme="gov.nih.nlm.semanticType.phsu" label="tramadol"/>
		<category term="C0042196" scheme="gov.nih.nlm.semanticType.topp" label="vaccinations"/>
		<category term="C0047166" scheme="gov.nih.nlm.semanticType.phsu" label="acetaminophen"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0062527" scheme="gov.nih.nlm.semanticType.imft" label="hepatitis B"/>
		<category term="C0063041" scheme="gov.nih.nlm.semanticType.phsu" label="leflunomide"/>
		<category term="C0083031" scheme="gov.nih.nlm.semanticType.imft" label="interleukin"/>
		<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
		<category term="C0173022" scheme="gov.nih.nlm.semanticType.orch" label="barriers"/>
		<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
		<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
		<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="disease-modifying antirheumatic drugs"/>
		<category term="C0245109" scheme="gov.nih.nlm.semanticType.phsu" label="Anakinra"/>
		<category term="C0245109" scheme="gov.nih.nlm.semanticType.phsu" label="anakinra"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0368582" scheme="gov.nih.nlm.semanticType.imft" label="antibodies"/>
		<category term="C0380909" scheme="gov.nih.nlm.semanticType.phsu" label="cyclosporine"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
		<category term="C0393022" scheme="gov.nih.nlm.semanticType.imft" label="Rituximab"/>
		<category term="C0393022" scheme="gov.nih.nlm.semanticType.imft" label="rituximab"/>
		<category term="C0432616" scheme="gov.nih.nlm.semanticType.imft" label="anti"/>
		<category term="C0441640" scheme="gov.nih.nlm.semanticType.hlca" label="taper"/>
		<category term="C0441640" scheme="gov.nih.nlm.semanticType.hlca" label="tapering"/>
		<category term="C0451615" scheme="gov.nih.nlm.semanticType.topp" label="pain relief"/>
		<category term="C0454366" scheme="gov.nih.nlm.semanticType.topp" label="step-up"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0608705" scheme="gov.nih.nlm.semanticType.phsu" label="SC"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0666743" scheme="gov.nih.nlm.semanticType.imft" label="infliximab"/>
		<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
		<category term="C0717758" scheme="gov.nih.nlm.semanticType.imft" label="Etanercept"/>
		<category term="C0717758" scheme="gov.nih.nlm.semanticType.imft" label="etanercept"/>
		<category term="C0744425" scheme="gov.nih.nlm.semanticType.topp" label="glucocorticoid therapy"/>
		<category term="C1122087" scheme="gov.nih.nlm.semanticType.imft" label="Adalimumab"/>
		<category term="C1122087" scheme="gov.nih.nlm.semanticType.imft" label="adalimumab"/>
		<category term="C1293132" scheme="gov.nih.nlm.semanticType.topp" label="anchor"/>
		<category term="C1301725" scheme="gov.nih.nlm.semanticType.hlca" label="documented"/>
		<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
		<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="tumor necrosis factor"/>
		<category term="C1527374" scheme="gov.nih.nlm.semanticType.topp" label="therapy groups"/>
		<category term="C1609165" scheme="gov.nih.nlm.semanticType.imft" label="Tocilizumab"/>
		<category term="C1609165" scheme="gov.nih.nlm.semanticType.imft" label="tocilizumab"/>
		<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="Abatacept"/>
		<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="abatacept"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C2353893" scheme="gov.nih.nlm.semanticType.imft" label="golimumab"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptide"/>
		<category term="C2930696" scheme="gov.nih.nlm.semanticType.phsu" label="Tofacitinib"/>
		<category term="C2930696" scheme="gov.nih.nlm.semanticType.phsu" label="tofacitinib"/>
		<category term="C2939437" scheme="gov.nih.nlm.semanticType.topp" label="chemoprophylaxis"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
		<category term="C3469597" scheme="gov.nih.nlm.semanticType.hlca" label="Drug Administration"/>
		<category term="C3469597" scheme="gov.nih.nlm.semanticType.hlca" label="drug administration"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="Glucocorticoids"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="Food"/>
		<category term="C3541968" scheme="gov.nih.nlm.semanticType.phsu" label="opioids"/>		<id>7490</id>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H2892723"/>
			<id>198323</id>
			<summary>
				<section label="Principles of management" id="2892723">
					<fragment>It is important to determine whether joint symptoms in patients with persistently symptomatic RA are due to active inflammatory arthritis or are the result of structural damage that is unlikely to respond to antiinflammatory drugs and to nonbiologic or biologic DMARDs.</fragment>
				</section>
			</summary>
			<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H5187547"/>
			<id>198325</id>
			<summary>
				<section label="Definition of resistance to initial DMARDs" id="5187547">
					<fragment>A requirement, in addition to DMARDs, for chronic glucocorticoid therapy in a dose of greater than about 5 to 7.5 mg/day of prednisone or equivalent to achieve or maintain remission or low disease activity after three to six months of treatment with DMARDs.</fragment>
				</section>
			</summary>
			<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C0744425" scheme="gov.nih.nlm.semanticType.topp" label="glucocorticoid therapy"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H5187547"/>
			<id>198326</id>
			<summary>
				<section label="Definition of resistance to initial DMARDs" id="5187547">
					<fragment>A requirement for multiple courses with glucocorticoids, in excess of doses used for chronic therapy, for the treatment of recurrent disease flares in patients whose medication doses have been increased to the maximally tolerated or acceptable level.</fragment>
				</section>
			</summary>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H109283721"/>
			<id>198330</id>
			<summary>
				<section label="Approach to drug therapy" id="109283721">
					<fragment>In patients resistant to initial therapy with DMARDs, we either add additional DMARDs or switch the patient to a different DMARD or DMARD combination, while also treating the active inflammation with antiinflammatory drug therapy.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H109283721"/>
			<id>198338</id>
			<summary>
				<section label="Approach to drug therapy" id="109283721">
					<fragment>In patients who have not achieved treatment goals after three to six months of MTX, we generally treat with MTX plus a tumor necrosis factor (TNF) inhibitor, particularly in patients with high levels of disease activity or with adverse prognostic features.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="tumor necrosis factor"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H109283721"/>
			<id>198339</id>
			<summary>
				<section label="Approach to drug therapy" id="109283721">
					<fragment>Abatacept may be used as an alternative to a TNF inhibitor.</fragment>
				</section>
			</summary>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="Abatacept"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H109283721"/>
			<id>198340</id>
			<summary>
				<section label="Approach to drug therapy" id="109283721">
					<fragment>"Triple therapy" is an acceptable alternative to MTX plus a TNF inhibitor.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H109283721"/>
			<id>198341</id>
			<summary>
				<section label="Approach to drug therapy" id="109283721">
					<fragment>In patients who do not achieve a satisfactory response with this combination within three to six months, we discontinue SSZ and HCQ and continue to administer MTX while adding a TNF inhibitor.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H109283721"/>
			<id>198342</id>
			<summary>
				<section label="Approach to drug therapy" id="109283721">
					<fragment>In patients who do not respond adequately to therapy with MTX plus an initial TNF inhibitor within three to six months, we generally switch to a different TNF inhibitor and continue therapy with MTX.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H109283721"/>
			<id>198343</id>
			<summary>
				<section label="Approach to drug therapy" id="109283721">
					<fragment>In patients who do not respond adequately to the therapies above, including MTX and trials of two TNF inhibitors, we use abatacept, tocilizumab, rituximab, or tofacitinib in place of the TNF inhibitor.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0393022" scheme="gov.nih.nlm.semanticType.imft" label="rituximab"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1609165" scheme="gov.nih.nlm.semanticType.imft" label="tocilizumab"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="abatacept"/>
			<category term="C2930696" scheme="gov.nih.nlm.semanticType.phsu" label="tofacitinib"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H109283721"/>
			<id>198344</id>
			<summary>
				<section label="Approach to drug therapy" id="109283721">
					<fragment>Importantly, we do NOT recommend combinations of biologic DMARDs, such as anakinra and a TNF inhibitor, or the combination of abatacept with either a TNF inhibitor or anakinra.</fragment>
				</section>
			</summary>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C0245109" scheme="gov.nih.nlm.semanticType.phsu" label="anakinra"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="abatacept"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H3026408"/>
			<id>198346</id>
			<summary>
				<section label="PRETREATMENT INTERVENTIONS" id="3026408">
					<fragment>A number of important precautions should be taken before using DMARDs, including laboratory assessment (complete blood count, serum creatinine, aminotransferases, and other studies as indicated), evaluation of comorbidities, vaccinations, and screening for hepatitis C, hepatitis B, and latent tuberculosis infection.</fragment>
				</section>
			</summary>
			<category term="C0042196" scheme="gov.nih.nlm.semanticType.topp" label="vaccinations"/>
			<category term="C0062527" scheme="gov.nih.nlm.semanticType.imft" label="hepatitis B"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H3026408"/>
			<id>198348</id>
			<summary>
				<section label="PRETREATMENT INTERVENTIONS" id="3026408">
					<fragment>A chest radiograph should be obtained prior to initiating treatment with methotrexate.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="methotrexate"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H2897438"/>
			<id>198351</id>
			<summary>
				<section label="RESISTANT TO INITIAL DMARD" id="2897438">
					<fragment>In patients with only mildly active disease when DMARDs were initiated, hydroxychloroquine (HCQ) or sulfasalazine (SSZ) may have been started, and the patient may not have received methotrexate (MTX).</fragment>
				</section>
			</summary>
			<category term="C0020336" scheme="gov.nih.nlm.semanticType.phsu" label="hydroxychloroquine"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="methotrexate"/>
			<category term="C0036078" scheme="gov.nih.nlm.semanticType.phsu" label="sulfasalazine"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H2897438"/>
			<id>198353</id>
			<summary>
				<section label="RESISTANT TO INITIAL DMARD" id="2897438">
					<fragment>In patients who have already been treated with MTX, combination therapy of MTX with a biologic DMARD or additional nonbiologic DMARDs is the next step.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H109285579"/>
			<id>198354</id>
			<summary>
				<section label="Resistant to HCQ and/or SSZ" id="109285579">
					<fragment>In patients resistant to three to six months of therapy with hydroxychloroquine (HCQ) or sulfasalazine (SSZ)for initially mildly active disease, we suggest adding an alternative DMARD, usually methotrexate (MTX);</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
			<category term="C0020336" scheme="gov.nih.nlm.semanticType.phsu" label="hydroxychloroquine"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="methotrexate"/>
			<category term="C0036078" scheme="gov.nih.nlm.semanticType.phsu" label="sulfasalazine"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H109285579"/>
			<id>198357</id>
			<summary>
				<section label="Resistant to HCQ and/or SSZ" id="109285579">
					<fragment>A therapeutic trial of greater than three months is generally used in patients with partial responses showing progressive improvement, particularly in those in this group with low levels of disease activity and with limited functional impairment.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H109285579"/>
			<id>198358</id>
			<summary>
				<section label="Resistant to HCQ and/or SSZ" id="109285579">
					<fragment>We prefer MTX over alternative nonbiologic and biologic DMARDs in such patients for several reasons.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H109285579"/>
			<id>198359</id>
			<summary>
				<section label="Resistant to HCQ and/or SSZ" id="109285579">
					<fragment>MTX typically serves as the "anchor" drug for the most commonly used DMARD combinations.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C1293132" scheme="gov.nih.nlm.semanticType.topp" label="anchor"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H109285579"/>
			<id>198362</id>
			<summary>
				<section label="Resistant to HCQ and/or SSZ" id="109285579">
					<fragment>Additionally, those patients with an inadequate response to MTX can be quickly identified and subsequently treated prior to the development of irreversible injury.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H109285579"/>
			<id>198363</id>
			<summary>
				<section label="Resistant to HCQ and/or SSZ" id="109285579">
					<fragment>There is also some evidence that risk may be greater with biologic agents, and, frequently, there are regulatory or cost barriers to the use of biologic therapies in patients who have not been treated with MTX.</fragment>
				</section>
			</summary>
			<category term="C0005527" scheme="gov.nih.nlm.semanticType.topp" label="biologic therapies"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0173022" scheme="gov.nih.nlm.semanticType.orch" label="barriers"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H109285579"/>
			<id>198364</id>
			<summary>
				<section label="Resistant to HCQ and/or SSZ" id="109285579">
					<fragment>Treatment with MTX is reviewed in detail separately, and the efficacy of such "triple therapy" with this DMARD combination is discussed in further detail below.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H12087126"/>
			<id>198365</id>
			<summary>
				<section label="Resistant to MTX" id="12087126">
					<fragment>In patients resistant to MTX after three to six months of treatment at optimal doses, we suggest either the combination of continued MTX plus a tumor necrosis factor (TNF) inhibitor or the use of DMARD "triple therapy" with MTX plus sulfasalazine (SSZ) and hydroxychloroquine (HCQ), rather than monotherapy with another nonbiologic or biologic DMARD.</fragment>
				</section>
			</summary>
			<category term="C0020336" scheme="gov.nih.nlm.semanticType.phsu" label="hydroxychloroquine"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0036078" scheme="gov.nih.nlm.semanticType.phsu" label="sulfasalazine"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="tumor necrosis factor"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H12087126"/>
			<id>198366</id>
			<summary>
				<section label="Resistant to MTX" id="12087126">
					<fragment>In patients with partial responses showing progressive improvement, we may continue therapy with MTX for greater than three months before switching to one of these approaches, particularly in those with low to moderate levels of disease activity and with limited functional impairment.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H12087126"/>
			<id>198367</id>
			<summary>
				<section label="Resistant to MTX" id="12087126">
					<fragment>Abatacept, the T-cell costimulation blocker, is an alternative to TNF inhibitors for use in combination with MTX in patients with an inadequate response to MTX, but its use in this setting is supported by a smaller body of evidence than that for TNF inhibitor use.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="Abatacept"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H12087126"/>
			<id>198369</id>
			<summary>
				<section label="Resistant to MTX" id="12087126">
					<fragment>Usual practice since TNF inhibitors came into clinical use beginning in the late 1990s has been to add a TNF inhibitor to MTX in patients with an inadequate response to MTX.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H12087126"/>
			<id>198370</id>
			<summary>
				<section label="Resistant to MTX" id="12087126">
					<fragment>Abatacept and tocilizumab have each generally been used in practice only following inadequate responses to both MTX and TNF inhibitors, although both of these biologic agents are available for use in the US for patients who have not responded adequately to MTX alone;</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1609165" scheme="gov.nih.nlm.semanticType.imft" label="tocilizumab"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="Abatacept"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H12087126"/>
			<id>198372</id>
			<summary>
				<section label="Resistant to MTX" id="12087126">
					<fragment>A further alternative for patients resistant to or unable to take MTX is leflunomide (LEF), an orally administered immunosuppressive agent, which may be used as monotherapy or in combination with either MTX or a TNF inhibitor.</fragment>
				</section>
			</summary>
			<category term="C0021081" scheme="gov.nih.nlm.semanticType.imft" label="immunosuppressive"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0063041" scheme="gov.nih.nlm.semanticType.phsu" label="leflunomide"/>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H12087392"/>
			<id>198374</id>
			<summary>
				<section label="Choice of therapy" id="12087392">
					<fragment>The choice of drug combinations in such patients depends upon a combination of factors, including the level of disease activity, patient preference for route of administration, the presence of adverse prognostic features, and regulatory and cost barriers to drug access.</fragment>
				</section>
			</summary>
			<category term="C0013162" scheme="gov.nih.nlm.semanticType.phsu" label="drug combinations"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0173022" scheme="gov.nih.nlm.semanticType.orch" label="barriers"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H12087392"/>
			<id>198375</id>
			<summary>
				<section label="Choice of therapy" id="12087392">
					<fragment>We prefer combination therapy with MTX plus a TNF inhibitor (eg, adalimumab, etanercept, or infliximab), particularly in patients with high levels of disease activity or with adverse prognostic features.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="C0666743" scheme="gov.nih.nlm.semanticType.imft" label="infliximab"/>
			<category term="C0717758" scheme="gov.nih.nlm.semanticType.imft" label="etanercept"/>
			<category term="C1122087" scheme="gov.nih.nlm.semanticType.imft" label="adalimumab"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H12087392"/>
			<id>198378</id>
			<summary>
				<section label="Choice of therapy" id="12087392">
					<fragment>We prefer triple therapy with MTX, sulfasalazine (SSZ), and hydroxychloroquine (HCQ) in patients for whom drug cost, regulatory restrictions on the use of biologic DMARDs, or preference for an oral agent that is not a biologic is an important factor.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0020336" scheme="gov.nih.nlm.semanticType.phsu" label="hydroxychloroquine"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0036078" scheme="gov.nih.nlm.semanticType.phsu" label="sulfasalazine"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H12087392"/>
			<id>198379</id>
			<summary>
				<section label="Choice of therapy" id="12087392">
					<fragment>In addition, concern regarding the risk of serious infections, the uncertain long-term increased risk of malignancy, and other possible adverse effects may influence clinician or patient preference for nonbiologic agents.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H12087392"/>
			<id>198381</id>
			<summary>
				<section label="Choice of therapy" id="12087392">
					<fragment>Abatacept may be used as an alternative to a TNF inhibitor in patients in whom MTX plus a TNF inhibitor would otherwise be appropriate, particularly in patients unable to use a TNF inhibitor and in patients with a high level of disease activity.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="Abatacept"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H12087392"/>
			<id>198383</id>
			<summary>
				<section label="Choice of therapy" id="12087392">
					<fragment>We generally prefer a TNF inhibitor over abatacept because the data supporting the use of abatacept are more limited than those available for the TNF inhibitors, although they suggest comparable benefit.</fragment>
				</section>
			</summary>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="abatacept"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H12087392"/>
			<id>198384</id>
			<summary>
				<section label="Choice of therapy" id="12087392">
					<fragment>LEF may be of particular benefit for patients in whom regulatory or cost considerations preclude use of a biologic agent, despite failure of MTX to adequately control disease activity.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H12087392"/>
			<id>198385</id>
			<summary>
				<section label="Choice of therapy" id="12087392">
					<fragment>It can be used in place of MTX in those patients who do not tolerate MTX, or it can be used in combination with MTX instead of adding a biologic agent.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H12087392"/>
			<id>198386</id>
			<summary>
				<section label="Choice of therapy" id="12087392">
					<fragment>It is also an option for patients who prefer not to use a parenterally administered drug.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011196"/>
			<id>198387</id>
			<summary>
				<section label="MTX plus TNF inhibitor" id="7011196">
					<fragment>In patients resistant to MTX, particularly those with high levels of disease activity or with adverse prognostic features, we prefer combination therapy with MTX plus a TNF inhibitor.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011196"/>
			<id>198388</id>
			<summary>
				<section label="MTX plus TNF inhibitor" id="7011196">
					<fragment>We usually use etanercept (50 mg administered subcutaneously once weekly) or adalimumab (40 mg administered subcutaneously every two weeks) as the initial TNF inhibitor in combination with continued MTX therapy, after appropriate pretreatment measures have been performed.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0717758" scheme="gov.nih.nlm.semanticType.imft" label="etanercept"/>
			<category term="C1122087" scheme="gov.nih.nlm.semanticType.imft" label="adalimumab"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011196"/>
			<id>198391</id>
			<summary>
				<section label="MTX plus TNF inhibitor" id="7011196">
					<fragment>In patients with an inadequate response to MTX, the use of combination therapy with the addition of a TNF inhibitor is supported by multiple randomized trials and meta-analyses that demonstrate the superiority of this approach compared with adding placebo while continuing the MTX.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011196"/>
			<id>198393</id>
			<summary>
				<section label="MTX plus TNF inhibitor" id="7011196">
					<fragment>Trials of MTX plus a TNF inhibitor in patients who have not responded adequately to MTX alone typically result in ACR20, ACR50, and ACR70 response rates of about 60, 40, and 20 percent, respectively.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011196"/>
			<id>198394</id>
			<summary>
				<section label="MTX plus TNF inhibitor" id="7011196">
					<fragment>Indirect comparisons of the biologic agents in meta-analyses of randomized trials involving patients with an inadequate response to MTX have shown a statistically nonsignificant trend suggesting that TNF inhibitors may be more likely to result in an ACR50 response compared with other biologic agents (odds ratio [OR] 1.30, 95% CI 0.91-1.86).</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011196"/>
			<id>198395</id>
			<summary>
				<section label="MTX plus TNF inhibitor" id="7011196">
					<fragment>Meta-analyses and randomized trials have also shown that combination therapy of MTX with a biologic agent, such as a TNF inhibitor, is superior to biologic or traditional DMARD monotherapy in patients who are naive to DMARDs.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011196"/>
			<id>198399</id>
			<summary>
				<section label="MTX plus TNF inhibitor" id="7011196">
					<fragment>Trials of biologic DMARDs and data supporting their use in patients with active RA are described in detail separately.</fragment>
				</section>
			</summary>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011196"/>
			<id>198400</id>
			<summary>
				<section label="MTX plus TNF inhibitor" id="7011196">
					<fragment>The evidence comparing the efficacy and safety of MTX plus a TNF inhibitor in this setting with those of nonbiologic DMARD triple therapy and with those of MTX plus abatacept are described in detail below.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="abatacept"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011196"/>
			<id>198403</id>
			<summary>
				<section label="MTX plus TNF inhibitor" id="7011196">
					<fragment>Etanercept and adalimumab might be safer than infliximab.</fragment>
				</section>
			</summary>
			<category term="C0666743" scheme="gov.nih.nlm.semanticType.imft" label="infliximab"/>
			<category term="C0717758" scheme="gov.nih.nlm.semanticType.imft" label="Etanercept"/>
			<category term="C1122087" scheme="gov.nih.nlm.semanticType.imft" label="adalimumab"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011196"/>
			<id>198405</id>
			<summary>
				<section label="MTX plus TNF inhibitor" id="7011196">
					<fragment>additionally, a case control study suggesting greater safety with etanercept, compared with infliximab or adalimumab, only addressed the risk of reactivation of latent tuberculosis in patients who had not received adequate chemoprophylaxis prior to therapy.</fragment>
				</section>
			</summary>
			<category term="C0666743" scheme="gov.nih.nlm.semanticType.imft" label="infliximab"/>
			<category term="C0717758" scheme="gov.nih.nlm.semanticType.imft" label="etanercept"/>
			<category term="C1122087" scheme="gov.nih.nlm.semanticType.imft" label="adalimumab"/>
			<category term="C2939437" scheme="gov.nih.nlm.semanticType.topp" label="chemoprophylaxis"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011196"/>
			<id>198406</id>
			<summary>
				<section label="MTX plus TNF inhibitor" id="7011196">
					<fragment>Indirect comparisons of randomized trial results in a network meta-analysis suggested that patients receiving etanercept, adalimumab, or golimumab had statistically significantly lower rates of withdrawal from trials due to adverse effects compared with infliximab (OR 0.63, 95% CI 0.41-0.95; OR 0.50, 95% CI 0.32-0.78; and OR 0.55, 95% CI 0.30-0.99).</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0666743" scheme="gov.nih.nlm.semanticType.imft" label="infliximab"/>
			<category term="C0717758" scheme="gov.nih.nlm.semanticType.imft" label="etanercept"/>
			<category term="C1122087" scheme="gov.nih.nlm.semanticType.imft" label="adalimumab"/>
			<category term="C2353893" scheme="gov.nih.nlm.semanticType.imft" label="golimumab"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011196"/>
			<id>198407</id>
			<summary>
				<section label="MTX plus TNF inhibitor" id="7011196">
					<fragment>TNF inhibitor therapy is generally well-tolerated, but these medications pose increased risk of reactivation of latent tuberculosis and other granulomatous diseases (eg, histoplasmosis and coccidiomycosis) and of varicella zoster.</fragment>
				</section>
			</summary>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011196"/>
			<id>198411</id>
			<summary>
				<section label="MTX plus TNF inhibitor" id="7011196">
					<fragment>TNF inhibitors should not be administered to patients with active infections or with multiple sclerosis.</fragment>
				</section>
			</summary>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011759"/>
			<id>198413</id>
			<summary>
				<section label="Efficacy of MTX/TNF inhibitor versus triple therapy" id="7011759">
					<fragment>Two randomized trials have compared the combination of MTX plus a TNF inhibitor with DMARD triple therapy combining MTX plus sulfasalazine (SSZ) and hydroxychloroquine (HCQ);</fragment>
				</section>
			</summary>
			<category term="C0020336" scheme="gov.nih.nlm.semanticType.phsu" label="hydroxychloroquine"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0036078" scheme="gov.nih.nlm.semanticType.phsu" label="sulfasalazine"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011759"/>
			<id>198417</id>
			<summary>
				<section label="Efficacy of MTX/TNF inhibitor versus triple therapy" id="7011759">
					<fragment>Both trials included a step-up design, in which patients were randomly assigned (either before or after initial treatment with MTX) to receive one of the two treatment options following an inadequate response to MTX: Swefot trial - The Swedish Pharmacotherapy (Swefot) trial compared the efficacy of MTX plus infliximab with that of triple therapy using MTX, SSZ, and HCQ.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="Pharmacotherapy"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0454366" scheme="gov.nih.nlm.semanticType.topp" label="step-up"/>
			<category term="C0666743" scheme="gov.nih.nlm.semanticType.imft" label="infliximab"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011759"/>
			<id>198424</id>
			<summary>
				<section label="Efficacy of MTX/TNF inhibitor versus triple therapy" id="7011759">
					<fragment>At 24 months, the mean increases in the van der Heijde-modified Sharp score (score range 0 to 448, reflecting radiographic detection of joint damage) were statistically significantly lower in the patients receiving infliximab compared with those receiving conventional DMARD triple therapy (4 versus 7.23, for a treatment difference of 3.23, 95% CI 0.14-6.32).</fragment>
				</section>
			</summary>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C0666743" scheme="gov.nih.nlm.semanticType.imft" label="infliximab"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011759"/>
			<id>198428</id>
			<summary>
				<section label="Efficacy of MTX/TNF inhibitor versus triple therapy" id="7011759">
					<fragment>patients were randomly assigned in this double-blind trial to receive one of the following: immediate treatment with MTX plus etanercept;</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0717758" scheme="gov.nih.nlm.semanticType.imft" label="etanercept"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011759"/>
			<id>198432</id>
			<summary>
				<section label="Efficacy of MTX/TNF inhibitor versus triple therapy" id="7011759">
					<fragment>Clinical outcomes (DAS28 scores) were comparable at 24 weeks in the two immediate combination therapy groups, which together showed a significantly greater reduction in disease activity compared with the two step-up groups (DAS28-ESR decrease of 4.2 versus 3.6) at this time point (prior to stepping up to combination therapy).</fragment>
				</section>
			</summary>
			<category term="C0454366" scheme="gov.nih.nlm.semanticType.topp" label="step-up"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="C1527374" scheme="gov.nih.nlm.semanticType.topp" label="therapy groups"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7011759"/>
			<id>198434</id>
			<summary>
				<section label="Efficacy of MTX/TNF inhibitor versus triple therapy" id="7011759">
					<fragment>Clinical outcomes, measured by the DAS28-ESR scores, were comparable during weeks 48 to 102 in patients receiving MTX plus etanercept or receiving triple therapy, regardless of whether they were initially assigned to immediate or step-up therapy.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0454366" scheme="gov.nih.nlm.semanticType.topp" label="step-up"/>
			<category term="C0717758" scheme="gov.nih.nlm.semanticType.imft" label="etanercept"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7012229"/>
			<id>198439</id>
			<summary>
				<section label="Efficacy of MTX/TNF inhibitor versus MTX/abatacept" id="7012229">
					<fragment>Two randomized trials have compared abatacept with a TNF inhibitor for use in combination with continued MTX therapy in patients with an inadequate response to MTX, suggesting comparable benefit and safety of the two regimens, with 60 to 70 percent of patients achieving an ACR20 response: ATTEST trial - In the "Abatacept or infliximab versus placebo, a Trial for Tolerability, Efficacy, and Safety in Treating rheumatoid arthritis" (ATTEST) trial, 431 patients with active RA and with an inadequate response to MTX were randomly assigned to receive abatacept (500, 750, or 1000 mg in patients weighing &lt;60 kg, 60 to 100 kg, or &gt;100 kg, respectively, by intravenous infusion on days 1, 15, and 29, then every four weeks), infliximab (3 mg/kg by intravenous infusion on days 1, 15, 43, and 85, then every eight weeks), or placebo infusions, while continuing background MTX.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="C0666743" scheme="gov.nih.nlm.semanticType.imft" label="infliximab"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="abatacept"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7012229"/>
			<id>198441</id>
			<summary>
				<section label="Efficacy of MTX/TNF inhibitor versus MTX/abatacept" id="7012229">
					<fragment>After one year of treatment, the frequency of ACR20 responses with abatacept plus MTX was statistically significantly greater than with infliximab plus MTX (72 versus 56 percent).</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0666743" scheme="gov.nih.nlm.semanticType.imft" label="infliximab"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="abatacept"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7012229"/>
			<id>198443</id>
			<summary>
				<section label="Efficacy of MTX/TNF inhibitor versus MTX/abatacept" id="7012229">
					<fragment>AMPLE trial - A preliminary report of the Abatacept versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate (AMPLE) trial, involving 646 patients with active RA and with an inadequate response to MTX, found comparable clinical and radiographic responses to MTX plus abatacept (125 mg administered subcutaneously weekly) and to MTX plus adalimumab (40 mg administered subcutaneously every two weeks) at one year (ACR20 of 65 and 63 percent, respectively, and increased modified total Sharp scores of 0.58 and 0.38 on a scale of 0 to 448, respectively).</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="Methotrexate"/>
			<category term="C1122087" scheme="gov.nih.nlm.semanticType.imft" label="Adalimumab"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="Abatacept"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013148"/>
			<id>198446</id>
			<summary>
				<section label="DMARD triple therapy" id="7013148">
					<fragment>Drug dosing is as follows: MTX is continued at the maximum tolerated dose achieved with initial therapy up to 25 mg once weekly.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drug"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013148"/>
			<id>198450</id>
			<summary>
				<section label="DMARD triple therapy" id="7013148">
					<fragment>HCQ is used at a dose of 400 mg daily in most patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013148"/>
			<id>198451</id>
			<summary>
				<section label="DMARD triple therapy" id="7013148">
					<fragment>The use of HCQ in rheumatic disease, including RA, as well as the dosing, adverse effects, and monitoring of HCQ, is discussed in detail separately.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013148"/>
			<id>198453</id>
			<summary>
				<section label="DMARD triple therapy" id="7013148">
					<fragment>The evidence describing the efficacy of triple therapy in patients who have had an inadequate response to MTX and comparing triple therapy with the combination of MTX plus a TNF inhibitor are described above;</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013515"/>
			<id>198455</id>
			<summary>
				<section label="Alternatives to MTX/TNF inhibitor and to triple therapy" id="7013515">
					<fragment>In some patients resistant to initial DMARD therapy with MTX, the use of abatacept as an alternative biologic to a TNF inhibitor or the use of leflunomide, an orally administered nonbiologic DMARD, in place of or in addition to MTX may be appropriate.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0063041" scheme="gov.nih.nlm.semanticType.phsu" label="leflunomide"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="abatacept"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013515"/>
			<id>198456</id>
			<summary>
				<section label="Alternatives to MTX/TNF inhibitor and to triple therapy" id="7013515">
					<fragment>We suggest the combination of MTX plus abatacept in patients in whom MTX plus a TNF inhibitor would otherwise be appropriate, particularly in patients who are unable to use a TNF inhibitor and who have a high level of disease activity.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="abatacept"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013515"/>
			<id>198457</id>
			<summary>
				<section label="Alternatives to MTX/TNF inhibitor and to triple therapy" id="7013515">
					<fragment>We suggest either switching to leflunomide (LEF) or adding LEF to ongoing MTX as therapeutic options for patients in whom regulatory or cost considerations preclude use of a biologic agent, despite failure of MTX to adequately control disease activity.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0063041" scheme="gov.nih.nlm.semanticType.phsu" label="leflunomide"/>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7014295"/>
			<id>198458</id>
			<summary>
				<section label="MTX plus abatacept" id="7014295">
					<fragment>Abatacept may be used as an alternative to a TNF inhibitor.</fragment>
				</section>
			</summary>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="Abatacept"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7014295"/>
			<id>198462</id>
			<summary>
				<section label="MTX plus abatacept" id="7014295">
					<fragment>It should not be used in combination with other biologic DMARDs, such as TNF inhibitors or anakinra.</fragment>
				</section>
			</summary>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C0245109" scheme="gov.nih.nlm.semanticType.phsu" label="anakinra"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7014295"/>
			<id>198463</id>
			<summary>
				<section label="MTX plus abatacept" id="7014295">
					<fragment>Meta-analyses of multiple randomized trials have documented the benefits of abatacept compared with placebo for use either alone or in combination with nonbiologic DMARDs.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C1301725" scheme="gov.nih.nlm.semanticType.hlca" label="documented"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="abatacept"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7014295"/>
			<id>198464</id>
			<summary>
				<section label="MTX plus abatacept" id="7014295">
					<fragment>In a systematic review and in indirect comparisons of randomized trial results from a network meta-analysis of biologic agents in patients with an inadequate response to MTX, the combination of abatacept with MTX was significantly more effective compared with MTX alone (ACR50 at 24 weeks of 32 versus 12 percent).</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="abatacept"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7014295"/>
			<id>198465</id>
			<summary>
				<section label="MTX plus abatacept" id="7014295">
					<fragment>Abatacept was comparable to other biologic agents, including several TNF inhibitors, rituximab, and tocilizumab.</fragment>
				</section>
			</summary>
			<category term="C0393022" scheme="gov.nih.nlm.semanticType.imft" label="rituximab"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1609165" scheme="gov.nih.nlm.semanticType.imft" label="tocilizumab"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="Abatacept"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7014295"/>
			<id>198468</id>
			<summary>
				<section label="MTX plus abatacept" id="7014295">
					<fragment>These include two randomized trials described above, which have suggested comparable benefit of abatacept to TNF inhibitor therapy when either is used in combination with continued MTX in patients with an inadequate response to MTX therapy.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="abatacept"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7014295"/>
			<id>198471</id>
			<summary>
				<section label="MTX plus abatacept" id="7014295">
					<fragment>The onset and magnitude of the responses, disease activity, improvements in physical function, and adverse effects were also comparable.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7014295"/>
			<id>198472</id>
			<summary>
				<section label="MTX plus abatacept" id="7014295">
					<fragment>Injection site reactions were mostly mild and were as frequent in patients receiving the active SC drug as in those receiving SC placebo (2.5 to 2.6 percent).</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0608705" scheme="gov.nih.nlm.semanticType.phsu" label="SC"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7014295"/>
			<id>198475</id>
			<summary>
				<section label="MTX plus abatacept" id="7014295">
					<fragment>Abatacept also appears to increase the risk of serious infections, including pneumonia, pyelonephritis, cellulitis, and diverticulitis.</fragment>
				</section>
			</summary>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="Abatacept"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7014295"/>
			<id>198477</id>
			<summary>
				<section label="MTX plus abatacept" id="7014295">
					<fragment>The overall safety of abatacept appears comparable to or, possibly, slightly better than that of the TNF inhibitors, although there are few direct comparisons.</fragment>
				</section>
			</summary>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="abatacept"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013910"/>
			<id>198481</id>
			<summary>
				<section label="Leflunomide" id="7013910">
					<fragment>The use of LEF alone, without MTX, is preferred in the absence of clinical improvement from prior treatment with the maximally tolerated dose of MTX within the usual therapeutic range, as well as in patients in whom there is a greater degree of concern for the possible increased risk of side effects with the combination of LEF and MTX.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013910"/>
			<id>198482</id>
			<summary>
				<section label="Leflunomide" id="7013910">
					<fragment>Although both drugs are potentially hepatotoxic, the rationale for combined therapy is based upon their differing mechanisms of action.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0033972" scheme="gov.nih.nlm.semanticType.topp" label="combined therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013910"/>
			<id>198483</id>
			<summary>
				<section label="Leflunomide" id="7013910">
					<fragment>In patients in whom LEF is used in place of MTX, the usual dose is 20 mg daily.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013910"/>
			<id>198486</id>
			<summary>
				<section label="Leflunomide" id="7013910">
					<fragment>Some experts continue to use a loading dose of LEF (100 mg daily for the first three days of therapy) in patients given LEF monotherapy, but other experts avoid the use of a loading dose because of increased risk of frequent bowel movements and of diarrhea with this approach.</fragment>
				</section>
			</summary>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013910"/>
			<id>198487</id>
			<summary>
				<section label="Leflunomide" id="7013910">
					<fragment>The use of LEF in patients with RA is discussed in detail separately.</fragment>
				</section>
			</summary>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013910"/>
			<id>198491</id>
			<summary>
				<section label="Leflunomide" id="7013910">
					<fragment>LEF had comparable efficacy to cyclosporine at 12 months of therapy in patients with an inadequate response to MTX (ACR50 of 40 versus 42 percent);</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0380909" scheme="gov.nih.nlm.semanticType.phsu" label="cyclosporine"/>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013910"/>
			<id>198492</id>
			<summary>
				<section label="Leflunomide" id="7013910">
					<fragment>however, LEF has not been compared directly with other agents in such patients.</fragment>
				</section>
			</summary>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013910"/>
			<id>198493</id>
			<summary>
				<section label="Leflunomide" id="7013910">
					<fragment>LEF has not been directly compared with the TNF inhibitors, but the superiority of TNF inhibitors is suggested by the comparability of LEF to sometimes suboptimal doses of MTX and to SSZ;</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013910"/>
			<id>198494</id>
			<summary>
				<section label="Leflunomide" id="7013910">
					<fragment>by the more rapid effects and greater overall benefit of TNF inhibitors when they have been directly compared with MTX or SSZ;</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013910"/>
			<id>198497</id>
			<summary>
				<section label="Leflunomide" id="7013910">
					<fragment>The combination of leflunomide and MTX is effective in patients who have not responded adequately to MTX alone.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0063041" scheme="gov.nih.nlm.semanticType.phsu" label="leflunomide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013910"/>
			<id>198502</id>
			<summary>
				<section label="Leflunomide" id="7013910">
					<fragment>Diarrhea and elevation of serum aminotransferases were the only adverse effects seen significantly more often with LEF plus MTX than with placebo plus MTX.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013910"/>
			<id>198503</id>
			<summary>
				<section label="Leflunomide" id="7013910">
					<fragment>Patients on both LEF and MTX may require closer monitoring (eg, monthly aminotransferase testing) for hepatotoxicity, given the increased risk of hepatotoxicity in some but not most studies, including reports of fatal liver failure.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7013910"/>
			<id>198505</id>
			<summary>
				<section label="Leflunomide" id="7013910">
					<fragment>In patients with an inadequate response to initial treatment with LEF alone, a TNF inhibitor may be added to LEF.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H2897506"/>
			<id>198508</id>
			<summary>
				<section label="REEVALUATION AND MONITORING" id="2897506">
					<fragment>Disease activity and the response to therapy should be regularly reassessed, along with monitoring for drug toxicities, every four to eight weeks following a change in the treatment regimen until the patient is stable and until disease is under control.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H2897506"/>
			<id>198511</id>
			<summary>
				<section label="REEVALUATION AND MONITORING" id="2897506">
					<fragment>more frequent clinical assessments may be required in patients experiencing a flare of disease or in those undergoing changes in therapy.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H2897506"/>
			<id>198514</id>
			<summary>
				<section label="REEVALUATION AND MONITORING" id="2897506">
					<fragment>We periodically reevaluate disease activity using a quantitative composite measure at each assessment (eg, the Clinical Disease Activity Index [CDAI] or the Disease Activity Score [DAS] with 28 joint count [DAS28]).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H2897506"/>
			<id>198515</id>
			<summary>
				<section label="REEVALUATION AND MONITORING" id="2897506">
					<fragment>Patients who fail to achieve remission or low disease activity within three to six months of initiating therapy or who require more than 5 mg/day of prednisone or equivalent glucocorticoid to maintain a state of remission should generally receive a more potent DMARD or combination of DMARDs.</fragment>
				</section>
			</summary>
			<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H2897506"/>
			<id>198516</id>
			<summary>
				<section label="REEVALUATION AND MONITORING" id="2897506">
					<fragment>A therapeutic trial of greater than three months is generally used in patients with partial responses showing progressive improvement, particularly in those with low to moderate levels of disease activity and with limited functional impairment.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H8152910"/>
			<id>198517</id>
			<summary>
				<section label="Resistant to one TNF inhibitor" id="8152910">
					<fragment>In patients who do not respond adequately to therapy with an initial TNF inhibitor within three months, we suggest switching to a different TNF inhibitor and continuing therapy with MTX.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H8152910"/>
			<id>198520</id>
			<summary>
				<section label="Resistant to one TNF inhibitor" id="8152910">
					<fragment>Some experts advocate switching to another class of biologic in patients who have experienced a serious adverse event (as defined by the US Food and Drug Administration [FDA]) with an initial TNF inhibitor.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drug"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C3469597" scheme="gov.nih.nlm.semanticType.hlca" label="Drug Administration"/>
			<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="Food"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H8152910"/>
			<id>198521</id>
			<summary>
				<section label="Resistant to one TNF inhibitor" id="8152910">
					<fragment>The FDA definition of a serious adverse event includes an adverse event associated with the use of a medical product that resulted in a life-threatening event, in hospitalization, prolongation of a hospitalization, in disability or permanent damage, in a congenital anomaly or birth defect in a child of a parent using the medication, or in an adverse event requiring intervention to prevent permanent impairment or damage.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H8152910"/>
			<id>198530</id>
			<summary>
				<section label="Resistant to one TNF inhibitor" id="8152910">
					<fragment>There was no increase in serious adverse events in patients on golimumab compared with those on placebo.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C2353893" scheme="gov.nih.nlm.semanticType.imft" label="golimumab"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H8152910"/>
			<id>198533</id>
			<summary>
				<section label="Resistant to one TNF inhibitor" id="8152910">
					<fragment>After three months of treatment, patients receiving their first compared with their second anti-TNF agent and patients receiving their second compared with their third anti-TNF agent were more likely to achieve an ACR20 (61 versus 51 versus 35 percent, respectively) or ACR50 response (37 versus 27 versus 18 percent, respectively).</fragment>
				</section>
			</summary>
			<category term="C0432616" scheme="gov.nih.nlm.semanticType.imft" label="anti"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H8152313"/>
			<id>198537</id>
			<summary>
				<section label="Resistant to two TNF inhibitors" id="8152313">
					<fragment>In patients who do not respond adequately to three- to six-month trials of the therapies above, including trials of MTX and trials of two TNF inhibitors, or who are unable to take a TNF inhibitor, we suggest the use of abatacept, tocilizumab, or rituximab, biologic agents which may all be effective in patients who have not responded adequately to MTX plus a TNF inhibitor.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0393022" scheme="gov.nih.nlm.semanticType.imft" label="rituximab"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1609165" scheme="gov.nih.nlm.semanticType.imft" label="tocilizumab"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="abatacept"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H8152313"/>
			<id>198539</id>
			<summary>
				<section label="Resistant to two TNF inhibitors" id="8152313">
					<fragment>Because the likelihood of a response decreases with second switches of TNF inhibitors, a change to a biologic DMARD other than a TNF inhibitor is suggested after the failure of two such agents.</fragment>
				</section>
			</summary>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7014677"/>
			<id>198542</id>
			<summary>
				<section label="Choice of therapy" id="7014677">
					<fragment>The choice between abatacept, tocilizumab, rituximab, and tofacitinib depends upon several factors, which vary in importance in different patients.</fragment>
				</section>
			</summary>
			<category term="C0393022" scheme="gov.nih.nlm.semanticType.imft" label="rituximab"/>
			<category term="C1609165" scheme="gov.nih.nlm.semanticType.imft" label="tocilizumab"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="abatacept"/>
			<category term="C2930696" scheme="gov.nih.nlm.semanticType.phsu" label="tofacitinib"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7014677"/>
			<id>198547</id>
			<summary>
				<section label="Choice of therapy" id="7014677">
					<fragment>They have not been directly compared, but abatacept, tocilizumab, and rituximab appear comparable in indirect comparisons of randomized trial data in a meta-analysis.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0393022" scheme="gov.nih.nlm.semanticType.imft" label="rituximab"/>
			<category term="C1609165" scheme="gov.nih.nlm.semanticType.imft" label="tocilizumab"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="abatacept"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7014677"/>
			<id>198549</id>
			<summary>
				<section label="Choice of therapy" id="7014677">
					<fragment>In patients who experience adverse effects from these agents, the immunosuppressive or immunomodulatory actions of these drugs are more rapidly reversed than those of rituximab, whose effects may last for several months or longer.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0021081" scheme="gov.nih.nlm.semanticType.imft" label="immunosuppressive"/>
			<category term="C0393022" scheme="gov.nih.nlm.semanticType.imft" label="rituximab"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7014677"/>
			<id>198554</id>
			<summary>
				<section label="Choice of therapy" id="7014677">
					<fragment>Rituximab may be preferred in patients in whom monthly drug administration may be problematic, as a treatment course of two IV infusions is administered no more frequently than every six months.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0393022" scheme="gov.nih.nlm.semanticType.imft" label="Rituximab"/>
			<category term="C3469597" scheme="gov.nih.nlm.semanticType.hlca" label="drug administration"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7014677"/>
			<id>198555</id>
			<summary>
				<section label="Choice of therapy" id="7014677">
					<fragment>Patients with rheumatoid factor or with anti-citrullinated peptide antibodies may have a greater response to the drug than seronegative patients.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0035448" scheme="gov.nih.nlm.semanticType.imft" label="rheumatoid factor"/>
			<category term="C0368582" scheme="gov.nih.nlm.semanticType.imft" label="antibodies"/>
			<category term="C0432616" scheme="gov.nih.nlm.semanticType.imft" label="anti"/>
			<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptide"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7014677"/>
			<id>198556</id>
			<summary>
				<section label="Choice of therapy" id="7014677">
					<fragment>Otherwise, the efficacy and safety of rituximab in patients with RA appear similar to those of other biologic agents.</fragment>
				</section>
			</summary>
			<category term="C0393022" scheme="gov.nih.nlm.semanticType.imft" label="rituximab"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7014677"/>
			<id>198558</id>
			<summary>
				<section label="Choice of therapy" id="7014677">
					<fragment>A potential advantage of this medication is that it is administered orally, but data regarding the risk of adverse events and outcomes with this drug compared with other antirheumatic medications are more limited compared with what is known regarding other available agents.</fragment>
				</section>
			</summary>
			<category term="C0003191" scheme="gov.nih.nlm.semanticType.phsu" label="antirheumatic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H7014677"/>
			<id>198559</id>
			<summary>
				<section label="Choice of therapy" id="7014677">
					<fragment>We prefer these agents over anakinra, as they all appear more effective than anakinra, based upon their comparability to biologic DMARDs that have been shown superior to anakinra in indirect comparisons.</fragment>
				</section>
			</summary>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C0245109" scheme="gov.nih.nlm.semanticType.phsu" label="anakinra"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H110291231"/>
			<id>198568</id>
			<summary>
				<section label="Tocilizumab" id="110291231">
					<fragment>Tocilizumab has been effective in patients with RA who have not responded adequately to TNF inhibitors.</fragment>
				</section>
			</summary>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1609165" scheme="gov.nih.nlm.semanticType.imft" label="Tocilizumab"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H110291231"/>
			<id>198569</id>
			<summary>
				<section label="Tocilizumab" id="110291231">
					<fragment>In a randomized trial involving 499 patients with an inadequate response to TNF inhibitor therapy, the use of tocilizumab (8 mg/kg and 4 mg/kg administered intravenously every four weeks, respectively), together with continued treatment with MTX, significantly improved treatment outcomes at six months compared with placebo plus MTX (ACR20 of 50 and 30 percent versus 10 percent).</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1609165" scheme="gov.nih.nlm.semanticType.imft" label="tocilizumab"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H110291231"/>
			<id>198571</id>
			<summary>
				<section label="Tocilizumab" id="110291231">
					<fragment>The rates of serious adverse events, serious infections, and adverse events leading to drug discontinuation were similar in all three groups;</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H110291231"/>
			<id>198572</id>
			<summary>
				<section label="Tocilizumab" id="110291231">
					<fragment>adverse events that were numerically more common in patients on tocilizumab included infections (49 and 47 percent versus 41 percent), gastrointestinal symptoms (37 and 33 percent versus 19 percent), and rash (22 and 31 percent versus 14 percent).</fragment>
				</section>
			</summary>
			<category term="C1609165" scheme="gov.nih.nlm.semanticType.imft" label="tocilizumab"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H110291231"/>
			<id>198573</id>
			<summary>
				<section label="Tocilizumab" id="110291231">
					<fragment>A dose adjustment or drug discontinuation may be required in patients with significant liver enzyme (aminotransferase) elevations, neutropenia, or thrombocytopenia.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H110291231"/>
			<id>198575</id>
			<summary>
				<section label="Tocilizumab" id="110291231">
					<fragment>The risk of adverse effects is greater in patients on concomitant immunosuppressive therapy.</fragment>
				</section>
			</summary>
			<category term="C0021079" scheme="gov.nih.nlm.semanticType.topp" label="immunosuppressive therapy"/>
			<category term="C0021081" scheme="gov.nih.nlm.semanticType.imft" label="immunosuppressive"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H110291285"/>
			<id>198580</id>
			<summary>
				<section label="Rituximab" id="110291285">
					<fragment>Similarly, we generally wait six months after administration of rituximab before switching to an alternative medication for lack of efficacy or for adverse effects because of the duration of its biologic effects.</fragment>
				</section>
			</summary>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="C0393022" scheme="gov.nih.nlm.semanticType.imft" label="rituximab"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H110291285"/>
			<id>198582</id>
			<summary>
				<section label="Rituximab" id="110291285">
					<fragment>The efficacy of rituximab plus continued therapy with MTX in patients with an inadequate response to a TNF inhibitor was shown in comparison with placebo plus continued MTX in a randomized trial involving 520 patients.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0393022" scheme="gov.nih.nlm.semanticType.imft" label="rituximab"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H110291285"/>
			<id>198583</id>
			<summary>
				<section label="Rituximab" id="110291285">
					<fragment>At six months, significantly more patients receiving rituximab showed at least 20 percent improvement in clinical activity compared with placebo treated patients (ACR20 of 51 versus 18 percent).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0393022" scheme="gov.nih.nlm.semanticType.imft" label="rituximab"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H110291285"/>
			<id>198585</id>
			<summary>
				<section label="Rituximab" id="110291285">
					<fragment>Additionally, a registry-based study suggested that, when the reason for stopping a TNF inhibitor was lack of effect rather than an adverse event, rituximab resulted in a greater decrease in disease activity compared with treatment with another TNF inhibitor (DAS28 decrease of -1.34 versus -0.93).</fragment>
				</section>
			</summary>
			<category term="C0393022" scheme="gov.nih.nlm.semanticType.imft" label="rituximab"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H110291293"/>
			<id>198589</id>
			<summary>
				<section label="Tofacitinib" id="110291293">
					<fragment>Tofacitinib can be used as monotherapy or combined with MTX or other nonbiologic DMARDs in patients with moderately to severely active RA who have had an inadequate response or intolerance to MTX, but it should not be taken in combination with biologic agents or with other potent immunosuppressants, such as azathioprine or cyclosporine.</fragment>
				</section>
			</summary>
			<category term="C0004482" scheme="gov.nih.nlm.semanticType.phsu" label="azathioprine"/>
			<category term="C0021081" scheme="gov.nih.nlm.semanticType.imft" label="immunosuppressants"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C0380909" scheme="gov.nih.nlm.semanticType.phsu" label="cyclosporine"/>
			<category term="C2930696" scheme="gov.nih.nlm.semanticType.phsu" label="Tofacitinib"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H110291293"/>
			<id>198593</id>
			<summary>
				<section label="Tofacitinib" id="110291293">
					<fragment>In a randomized trial involving 717 patients, tofacitinib (5 mg twice daily) and adalimumab (40 mg administered subcutaneously every two weeks) showed similarly significant benefit compared with placebo after six months in patients with active RA who had had an inadequate response to MTX and who continued MTX cotherapy (ACR20 of 52 and 47 percent versus 28 percent, respectively).</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C1122087" scheme="gov.nih.nlm.semanticType.imft" label="adalimumab"/>
			<category term="C2930696" scheme="gov.nih.nlm.semanticType.phsu" label="tofacitinib"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H110291293"/>
			<id>198594</id>
			<summary>
				<section label="Tofacitinib" id="110291293">
					<fragment>The relative safety of tofacitinib appeared similar to that of biologic DMARDs, including increased risk of infections and liver function test abnormalities;</fragment>
				</section>
			</summary>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C2930696" scheme="gov.nih.nlm.semanticType.phsu" label="tofacitinib"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H110291293"/>
			<id>198597</id>
			<summary>
				<section label="Tofacitinib" id="110291293">
					<fragment>The need for concurrent MTX therapy with use of tofacitinib is uncertain and requires further study.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C2930696" scheme="gov.nih.nlm.semanticType.phsu" label="tofacitinib"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H266402509"/>
			<id>198601</id>
			<summary>
				<section label="Resistant to standard therapies" id="266402509">
					<fragment>Nonbiologic (traditional) DMARDs - Treatment options in this setting should include the use of nonbiologic DMARDs, such as leflunomide, or DMARD combinations, such as triple therapy, which were not used in the original sequence of drug regimens in a given patient.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0063041" scheme="gov.nih.nlm.semanticType.phsu" label="leflunomide"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H266402509"/>
			<id>198603</id>
			<summary>
				<section label="Resistant to standard therapies" id="266402509">
					<fragment>Anakinra - The interleukin-1 receptor antagonist, anakinra, can be used in combination with MTX but appears less effective than other biologic DMARDs in RA.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0083031" scheme="gov.nih.nlm.semanticType.imft" label="interleukin"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C0245109" scheme="gov.nih.nlm.semanticType.phsu" label="Anakinra"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H266402509"/>
			<id>198604</id>
			<summary>
				<section label="Resistant to standard therapies" id="266402509">
					<fragment>Its effectiveness in patients who have failed to respond to MTX plus a TNF inhibitor has not been evaluated.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H266402509"/>
			<id>198605</id>
			<summary>
				<section label="Resistant to standard therapies" id="266402509">
					<fragment>Other nonbiologic traditional DMARDs - Nonbiologic DMARDs that have less efficacy, greater toxicity, or both, compared with other available medications, but that may be of use in patients without other treatment options include: Azathioprine.</fragment>
				</section>
			</summary>
			<category term="C0004482" scheme="gov.nih.nlm.semanticType.phsu" label="Azathioprine"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H109285013"/>
			<id>198610</id>
			<summary>
				<section label="Antiinflammatory therapy" id="109285013">
					<fragment>We use NSAIDs or systemic and/or intraarticular glucocorticoids when needed for ongoing control of inflammation, while awaiting the response to modifications in DMARD therapy.</fragment>
				</section>
			</summary>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAIDs"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H109285013"/>
			<id>198611</id>
			<summary>
				<section label="Antiinflammatory therapy" id="109285013">
					<fragment>Glucocorticoids can help to rapidly control inflammation and to improve symptoms.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="Glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H109285224"/>
			<id>198615</id>
			<summary>
				<section label="Drug therapy for flares" id="109285224">
					<fragment>It is important to distinguish a disease flare, characterized by symptoms and by physical and laboratory findings of increased inflammatory synovitis, from noninflammatory causes of local or generalized increased pain.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H2990265"/>
			<id>198618</id>
			<summary>
				<section label="Analgesics" id="2990265">
					<fragment>In addition to the medications noted above, including NSAIDs, which also have analgesic effects, we use other analgesic medications, such as acetaminophen and/or tramadol, for additional pain relief, if required.</fragment>
				</section>
			</summary>
			<category term="C0002771" scheme="gov.nih.nlm.semanticType.phsu" label="analgesic"/>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAIDs"/>
			<category term="C0040610" scheme="gov.nih.nlm.semanticType.phsu" label="tramadol"/>
			<category term="C0047166" scheme="gov.nih.nlm.semanticType.phsu" label="acetaminophen"/>
			<category term="C0451615" scheme="gov.nih.nlm.semanticType.topp" label="pain relief"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H2990265"/>
			<id>198619</id>
			<summary>
				<section label="Analgesics" id="2990265">
					<fragment>We generally avoid the use of potent opioids because pain can be controlled in most patients with RA by effective use of antiinflammatories and DMARDs that control the disease process.</fragment>
				</section>
			</summary>
			<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatories"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C3541968" scheme="gov.nih.nlm.semanticType.phsu" label="opioids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H2990265"/>
			<id>198620</id>
			<summary>
				<section label="Analgesics" id="2990265">
					<fragment>Patients without evidence of very significant joint injury who appear to require opioids for adequate pain relief should be evaluated for fibromyalgia or other comorbid causes of pain (eg, fracture, tumor, spinal disorders, or others).</fragment>
				</section>
			</summary>
			<category term="C0451615" scheme="gov.nih.nlm.semanticType.topp" label="pain relief"/>
			<category term="C3541968" scheme="gov.nih.nlm.semanticType.phsu" label="opioids"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H8152320"/>
			<id>198624</id>
			<summary>
				<section label="DURATION OF THERAPY" id="8152320">
					<fragment>Although some patients may tolerate a reduced dose of medications, the decision to discontinue DMARDs in patients in remission remains controversial, and there is limited evidence regarding tapering of DMARDs in patients who are started on DMARDs early in their disease course or who have been treated with biologic DMARDs.</fragment>
				</section>
			</summary>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARDs"/>
			<category term="C0441640" scheme="gov.nih.nlm.semanticType.hlca" label="tapering"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H8152320"/>
			<id>198626</id>
			<summary>
				<section label="DURATION OF THERAPY" id="8152320">
					<fragment>As an example of our approach, in a patient in clinical remission being treated with prednisone (7 mg/day), MTX (20 mg/week), and etanercept (50 mg/week), we would first try to reduce prednisone because of the risk of long-term adverse effects with glucocorticoids.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
			<category term="C0717758" scheme="gov.nih.nlm.semanticType.imft" label="etanercept"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H8152320"/>
			<id>198628</id>
			<summary>
				<section label="DURATION OF THERAPY" id="8152320">
					<fragment>If prednisone can be discontinued or if it cannot be completely eliminated but can be lowered to a dose no greater than 5 mg/day, we would then reduce the dosing of the TNF inhibitor, based upon our clinical experience.</fragment>
				</section>
			</summary>
			<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H8152320"/>
			<id>198630</id>
			<summary>
				<section label="DURATION OF THERAPY" id="8152320">
					<fragment>In patients on infliximab, in whom dose adjustment is more feasible compared with etanercept or adalimumab, we would try to incrementally reduce the dose to as low as 3 mg/kg and to increase the interval between infusions to every eight weeks.</fragment>
				</section>
			</summary>
			<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
			<category term="C0666743" scheme="gov.nih.nlm.semanticType.imft" label="infliximab"/>
			<category term="C0717758" scheme="gov.nih.nlm.semanticType.imft" label="etanercept"/>
			<category term="C1122087" scheme="gov.nih.nlm.semanticType.imft" label="adalimumab"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H8152320"/>
			<id>198634</id>
			<summary>
				<section label="DURATION OF THERAPY" id="8152320">
					<fragment>The risk of disease recurrence in such patients is high, and flares of disease may occur even several years after stopping therapy.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H16"/>
			<id>198651</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>Patient education and other nonpharmacologic and preventive therapies, including appropriate immunizations, are needed for all patients with RA.</fragment>
				</section>
			</summary>
			<category term="C0020971" scheme="gov.nih.nlm.semanticType.topp" label="immunizations"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H16"/>
			<id>198652</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>In patients with RA, resistance to initial therapy with disease-modifying antirheumatic drugs (DMARDs) is defined as failure to achieve remission or low disease activity within three to six months despite the use of maximally tolerated doses within the usual therapeutic range;</fragment>
				</section>
			</summary>
			<category term="C0003191" scheme="gov.nih.nlm.semanticType.phsu" label="antirheumatic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="disease-modifying antirheumatic drugs"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H16"/>
			<id>198655</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>In patients with active RA resistant to initial therapy after three to six months of treatment, we recommend treatment with a different or additional DMARD or with DMARD combinations to achieve control of signs and symptoms of disease, rather than continuing the initial DMARD regimen.</fragment>
				</section>
			</summary>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H16"/>
			<id>198656</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>The choice of drug combinations in such patients depends upon prior therapy, upon the level of disease activity, upon patient preference for route of administration, upon the presence of adverse prognostic features, and upon regulatory and cost barriers to drug access.</fragment>
				</section>
			</summary>
			<category term="C0013162" scheme="gov.nih.nlm.semanticType.phsu" label="drug combinations"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0173022" scheme="gov.nih.nlm.semanticType.orch" label="barriers"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H16"/>
			<id>198657</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>In patients resistant to initial therapy with hydroxychloroquine (HCQ) or sulfasalazine (SSZ), we suggest adding methotrexate (MTX) or treating with a combination of HCQ, SSZ, and MTX, rather than switching to a TNF inhibitor or to a TNF inhibitor plus MTX.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
			<category term="C0020336" scheme="gov.nih.nlm.semanticType.phsu" label="hydroxychloroquine"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="methotrexate"/>
			<category term="C0036078" scheme="gov.nih.nlm.semanticType.phsu" label="sulfasalazine"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H16"/>
			<id>198658</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>Usual doses of these medications are MTX (up to 25 mg once weekly administered orally or parenterally), HCQ (400 mg daily taken orally), and SSZ (1000 mg twice daily taken orally).</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H16"/>
			<id>198659</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>In patients who have not achieved treatment goals after three to six months of MTX at optimal doses, we suggest either the combination of continued MTX plus a tumor necrosis factor (TNF) inhibitor (eg, etanercept or adalimumab) or the use of DMARD "triple therapy" with MTX plus SSZ and HCQ, rather than monotherapy with another nonbiologic or biologic DMARD.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C0717758" scheme="gov.nih.nlm.semanticType.imft" label="etanercept"/>
			<category term="C1122087" scheme="gov.nih.nlm.semanticType.imft" label="adalimumab"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="tumor necrosis factor"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H16"/>
			<id>198662</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>In patients in whom MTX plus a TNF inhibitor would otherwise be appropriate but who are unable to use a TNF inhibitor, we suggest the combination of MTX plus abatacept, rather than biologic monotherapy or another DMARD combination.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="abatacept"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H16"/>
			<id>198664</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>In patients in whom regulatory or cost considerations preclude use of a biologic agent despite failure of MTX or DMARD triple therapy to adequately control disease activity, we suggest the use of leflunomide (LEF) rather than alternative nonbiologic DMARDs (eg, gold, azathioprine, or cyclosporine.</fragment>
				</section>
			</summary>
			<category term="C0004482" scheme="gov.nih.nlm.semanticType.phsu" label="azathioprine"/>
			<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="gold"/>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0063041" scheme="gov.nih.nlm.semanticType.phsu" label="leflunomide"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C0380909" scheme="gov.nih.nlm.semanticType.phsu" label="cyclosporine"/>
			<category term="C0672527" scheme="gov.nih.nlm.semanticType.aapp" label="LEF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H16"/>
			<id>198665</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>In patients who do not respond adequately to the therapies above, including trials of MTX and trials of two TNF inhibitors, we suggest the use of abatacept, tocilizumab, or rituximab, rather than the administration of a third TNF inhibitor.</fragment>
				</section>
			</summary>
			<category term="C0025677" scheme="gov.nih.nlm.semanticType.phsu" label="MTX"/>
			<category term="C0393022" scheme="gov.nih.nlm.semanticType.imft" label="rituximab"/>
			<category term="C1456820" scheme="gov.nih.nlm.semanticType.imft" label="TNF"/>
			<category term="C1609165" scheme="gov.nih.nlm.semanticType.imft" label="tocilizumab"/>
			<category term="C1619966" scheme="gov.nih.nlm.semanticType.phsu" label="abatacept"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H16"/>
			<id>198671</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>We continue nonbiologic and biologic DMARD therapy at reduced doses, if possible, for patients in remission, rather than discontinuing treatment with DMARDs.</fragment>
				</section>
			</summary>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H16"/>
			<id>198672</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>In patients experiencing a disease flare that is not controlled with NSAIDs, we suggest treatment with intraarticular or oral glucocorticoids rather than switching or continuing NSAIDs as the only additional agent.</fragment>
				</section>
			</summary>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="NSAIDs"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H16"/>
			<id>198673</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>We use antiinflammatory drug therapy, including nonsteroidal antiinflammatory drugs (NSAIDs) or glucocorticoids, on a temporary basis to quickly achieve control of signs and symptoms of disease, and we then taper and withdraw these medications once a new DMARD regimen has taken effect.</fragment>
				</section>
			</summary>
			<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
			<category term="C0003211" scheme="gov.nih.nlm.semanticType.phsu" label="nonsteroidal antiinflammatory drugs"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0242708" scheme="gov.nih.nlm.semanticType.phsu" label="DMARD"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0441640" scheme="gov.nih.nlm.semanticType.hlca" label="taper"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7490#H16"/>
			<id>198674</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>Some patients benefit from chronic low-dose glucocorticoid therapy (eg, prednisone to 5 to 7.5 mg daily).</fragment>
				</section>
			</summary>
			<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
			<category term="C0744425" scheme="gov.nih.nlm.semanticType.topp" label="glucocorticoid therapy"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
</aggregateKnowledgeResponse>
